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1.0 INTRODUCTION 
Peripheral blood stem cells (PBSC) have been used for transplantation 
since the early 1990s, and they are increasingly replacing bone marrow as a 
main source of stem cells. PBSC apparently have a number of advantages such 
as ease of collection without anesthesia and a more rapid engraftment following 
high dose chemotherapy. Moreover, tumour contamination is reduced and a 
sufficient number of PBSC can be harvested for sequential high dose 
chemotherapy cycles (Beyer et al., 1995).  
Although PBSC have been harvested and transplanted for more than 10 
years, more information about the release of progenitor cells from the bone 
marrow into the peripheral blood and their collection efficiency during apheresis 
is needed. It is well accepted that there is a small number of circulating 
progenitor cells in the peripheral blood in normal healthy individuals and that 
this number can be increased dramatically by a wide variety of mobilization 
stimuli, meaning that progenitor cells can be recruited into the peripheral blood 
during PBSC collection (Zingsem et al., 1992; Hillyer et al., 1993; Murea et al., 
1996; Fliedner, 1998; Humpe et al., 1999; Smolowicz et al., 1999; Rowley et al., 
2001). However, there were still patients that mobilized only low amounts of 
progenitor cells following the mobilization stimuli, which were insufficient for 
transplantation (Rick et al., 2000) 
For the identification and quantification of these haematopoietic 
progenitor cells, a surface CD34 marker is used. This is mainly because almost 
all hematopoietic progenitor cells express CD34 antigen. The CD34 antigen is a 
family of differentially glycosylated type 1 transmembrane single chain 
glycoproteins. The levels of CD34
+
 cells are very low in the peripheral blood of 
unmobilized individuals, approximately 0.1% of total nucleated cells in the 
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peripheral blood. This CD34+ cells are markedly increased after being 
mobilized by chemotherapy and/or growth factors. However, the levels of 
peripheral blood CD34
+
 cell counts for pre- and post-apheresis and the numbers 
of collected CD34
+
 cells are variable between patients (Rowley, 2001). The 
higher peripheral blood CD34
+
 cell counts following apheresis as compared to 
pre-apheresis peripheral blood CD34
+
 cell counts had been observed in a 
number of patients despite the fact that a significant amount of PBSC have been 
collected. This finding may support the hypothesis that the apheresis procedure 
itself may help in the recruitment and mobilization of progenitor cells from the 
bone marrow.  
Therefore, in this study, the analysis of pre and post apheresis peripheral 
blood CD34
+
 cells as well as the harvested CD34
+
 cells count have been carried 
out, to compare and correlate these result in order to have better understanding 
of the correlation of peripheral blood CD34
+
 cell counts and harvested stem cell 
count. The results obtained may help to provide information for further 
improvement of the collection efficiency and thus the PBSC yield for successful 
transplantation.  
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1.1 OBJECTIVE 
The general objective of this study is to determine the collection efficiency of 
peripheral blood stem cell harvesting using peripheral blood CD34
+
 cells 
quantification. 
The specific objectives of this study were: 
1. To determine the peripheral blood CD34
+
 cell counts pre and post 
apheresis and the stem cell yield. 
2. To correlate the PBSC yield and pre-apheresis peripheral blood 
CD34
+
 cell counts. 
3. To evaluate the cut-off value of pre-apheresis peripheral blood 
before performing PBSC harvesting. 
4. To correlate the day 1 post-apheresis peripheral blood CD34
+
 
cells and the day 2 pre-apheresis peripheral blood CD34
+
 cell 
counts. 
5. To correlate the day 1 post-apheresis peripheral blood CD34
+
 
cells and day 2 stem cell yield. 
6. To determine the collection efficiencies of CD34
+
 cells. 
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2.0 LITERATURE REVIEW 
2.1 STEM CELL 
2.1.1 Introduction 
The stem cell is the origin of life. “All cells come from cells”, as stated 
first by the great pathologist Rudolph Virchow. Stem cells have been found in 
most of the multi-cellular organisms. Stem cell is a special kind of cell that has a 
unique capacity. Although most cells of the body, are committed to conduct a 
specific function such as heart cells or skin cells, stem cell are uncommitted and 
remains uncommitted, until it receives a signal to develop into specialized cells. 
Their proliferative capacity combined with the ability to develop into specialized 
cells makes stem cells unique (Joanna et al., 2004).  
The classical definition of a stem cell requires that it possess two 
properties which are;  
i) self-renewal that means the ability to go through numerous cycles of 
 cell division while maintaining the undifferentiated state and potency. 
ii) the capacity to differentiate into specialized cell types. The stem cells 
 have varying degrees of differentiation potential. This ranges from 
 totipotent (ability to form the embryo and the trophoblast of the placenta 
 of the fertilised oocyte), pluripotent (ability to differentiate into almost 
 all cells that arise from the three germ layers of embryonic stem cells), 
 multipotent (capability of producing a limited range of differentiated cell 
 lineages appropriate to their location of most tissue based stem cells) and 
 unipotent (only able to generate to one cell types of cells such as the 
 epidermal stem cells and the spermatogonial cells of the testis (Preston 
 et al., 2003). 
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 2.1.2 Types of Stem Cell 
The two major types of mammalian stem cells are embryonic stem cell and adult 
stem cell. 
i) Embryonic Stem Cell 
An embryonic stem cell is derived from embryos at a developmental 
stage before the time that implantation would normally occur in the uterus. 
Fertilization normally occurs in the oviduct, and during the next few days, a 
series of cleavage divisions occur as the embryo travels down the oviduct and 
into the uterus. Each of the cells (blastomeres) of these cleavage-stage embryos 
are undifferentiated. They do not look or act like the specialized cells of the 
adult, and the blastomeres are not yet committed to becoming any particular type 
of differentiated cell. Indeed, each of these blastomere has the potential to give 
rise to any cell of the body (Thomson et al., 1998).  
The first differentiation event in humans occurs at approximately five 
days of development, when an outer layer of cells committed to becoming part 
of the placenta (the trophectoderm) separates from the inner cell mass (ICM). 
The ICM cells have the potential to generate any cell type of the body, but after 
implantation, they are quickly depleted as they differentiate to other cell types 
with more limited developmental potential. However, if the ICM is removed 
from its normal embryonic environment and cultured under appropriate 
conditions, the ICM-derived cells can continue to proliferate and replicate 
themselves indefinitely and still maintain the developmental potential to form 
any cell type of the body (Thomson et al., 1998). 
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Figure 1: Characteristics of Embryonic Stem Cells (adopted from Terese, 2001) 
 
In a developing embryo, stem cells can differentiate into all of the 
specialized embryonic tissues. In other words, they can develop into each of the 
more than 200 cell types of the adult body when given sufficient and necessary 
stimulation for a specific cell type. 
 
 
 
 
 
 7 
ii) Adult Stem Cell  
The term adult stem cell refers to any cell which is found in a developed 
organism that has two properties, which are the ability to self-renew and make 
identical copies of itself for the lifetime of the organism and also to differentiate 
into mature cell types that have characteristic, shapes and specialized functions. 
It is also known as somatic stem cells (from Greek word which means "of the 
body").  
The primary functions of adult stem cells are to maintain the steady state 
of a cell called homeostasis, to replace cells that died because of injury or 
disease (Holtzer, 1978 and Leblond, 1964). For example, only an estimated 1 in 
10,000 to 15,000 cells in the bone marrow is a hematopoietic (bloodforming) 
stem cell (Weissman, 2000).  
Furthermore, adult stem cells are dispersed in tissues throughout the 
mature animal and behave very differently, depending on their local 
environment. For example, stem cells in the small intestine are stationary, and 
are physically separated from the mature cell types they generate but in contrast, 
hematopoietic stem cells (HSC) are constantly being generated in the bone 
marrow where they differentiate into mature types of blood cells.  
HSC give rise to all the blood cell types including myeloid (monocytes 
and macrophages, neutrophils, basophils, eosinophils, erythrocytes, 
megakaryocytes/platelets, dendritic cells), and lymphoid lineages (T-cells, B-
cells, NK-cells). Indeed, they are ultimately responsible for the constant renewal 
of blood; the production of billions of new blood cells each day (Domen and 
Weissman, 1999) as shown in Figure 2. 
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    Figure 2: Hematopoietic and stromal cell differentiation (adopted from Terese, 2001) 
 
Adult stem cells have been successfully used for many years to treat 
leukemia and related blood cancers through hematopoietic stem cell 
transplantation with either bone-marrow-derived stem cell or mobilised 
peripheral blood stem cell. 
 
 
 
 
 
 
 
 
 
 
 9 
2.2 HEMATOPOIETIC STEM CELL TRANSPLANTATION 
2.2.1 Introduction 
Hematopoietic stem cell transplantation (HSCT) is the transplantation of 
pluripotential hematopoietic stem cell that derived from bone marrow, umbilical 
cord blood or peripheral blood stem cells.  HSCT was pioneered using bone-
marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research 
Center led by E. Donnall Thomas. They showed that the destroyed bone marrow 
may be repopulated by intravenous infusion of cellular suspensions of marrow 
taken from healthy donors (Thomas et al., 1957). HSCT has evolved rapidly 
over recent decades and widely applied in a variety of haematological 
malignancies and non-malignant diseases.  
 
2.2.2 Types of Hematopoietic Stem Cell Transplantation (HSCT) 
i) Autologous HSCT 
Autologous HSCT means transplantation using the patient‟s own stem 
cells. The stem cells were collected from the patient through a bone marrow 
harvest or apheresis procedure when the patient has achieved minimal residual 
disease or in remission. The stem cell product is then cryopreserved before 
storage in the cryogenic freezer to preserve the integrity of the stem cells and to 
maintain the optimum viability after thawing for transplantation.  
The patient is then treated with high-dose conditioning chemotherapy 
with or without radiotherapy with the intention of eradicating the patient's 
malignant cell population. The patient's own stored stem cells are then reinfused 
into his/her body, where these stem cells will home to the bone marrow and 
proliferate to resume the patient's normal blood cell production. 
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Autologous HSCT have several advantages such as low risk of infection 
during the immune-compromised portion of the treatment since the recovery of 
immune function is rapid and graft versus host disease (GVHD) is very rare due 
to the donor and recipient being the same individual. These advantages have 
enabled autologous HSCT to be established as one of the standard second-line 
treatment for lymphoma (Canellos and George, 1997).   
ii) Allogeneic HSCT 
Allogeneic HSCT means that the stem cells were obtained from a donor. 
Allogeneic HSC donors must have the same human leukocyte antigen (HLA) as 
the recepient to limit the risks of transplanted stem cell rejection or severe 
GVHD. Allogeneic HSC donors may be a closely HLA matched sibling, an 
identical twin of the patient (syngeneic) or an unrelated donor but found to have 
very close degree of HLA matching. Usually an identical twin is a source of 
perfectly HLA matched stem cells.  
Matching is performed on the basis of variability at three or more loci of 
the HLA loci, and a perfect match at these loci is preferred. The HLA antigens 
fall in two categories; Class I and Class II. In general, mismatches of the Class I 
antigen such as HLA-A, HLA-B, or HLA-C will increase the risk of graft 
rejection. A mismatch of an HLA Class II antigen for example HLA-DR, or 
HLA- DQB1 will increase the risk of graft-versus-host disease.  
In addition, a genetic mismatch as small as a single DNA base pair is 
significant so perfect matches require knowledge of the exact DNA sequence of 
these genes for both donor and recipient. Furthermore, race and ethnicity are 
also known to play a major role in donor selection for unrelated donor as 
members of the same ethnic group are more likely to have matching genes, 
including the genes for HLA (Cutler and Antin, 2001).   
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In general, by transplantation of healthy stem cells to the recipient, 
allogeneic HCST appear to improve the chances for cure or long-term remission 
once the immediate transplant-related complications are resolved (Russell et al., 
2000). Therefore, the allogeneic treatment may be preferred for Acute Myeloid 
Leukemia (Bruno et al., (2007) but the risk of acute and chronic GVHD is much 
more higher compared to autologous HSCT. 
 
2.2.3 Sources of HSC  
 
i) Bone Marrow 
Bone marrow is the standard source of HSC for transplantation. The 
HSC are aspirated from the bone marrow of the donor, typically at the pelvis 
bone. This is done by  using a large needle and syringe to draw out the bone 
marrow cells and the donor has to be under general anesthesia. This technique is 
referred to as a bone marrow harvest and shown in Figure 3.                 
        
Figure 3: Bone Marrow Harvest 
About 1 in every 100,000 cells in the marrow is a long term blood-
forming stem cell and the other cells present include stromal cells, stromal stem 
 12 
cells, blood progenitor cells and mature and maturing white and red blood cells 
(Liliane et al., 2001). 
 
ii) Umbilical Cord Blood 
 
In the late 1980s, physicians began to recognize that blood from the 
human umbilical cord as an important clinical source of HSC. The umbilical 
cord supports the developing fetus during pregnancy and is delivered along with 
the baby and it is normally discarded. The collection and therapeutic use of these 
cells has grown since the first successful umbilical cord blood transplant in a 
child with Fanconi anemia (Barker and Wagner, 2003).  
The concentration of HSC in umbilical cord blood (UCB) is lower than 
in adult blood due to the limited number of cells that may be harvested (typically 
about 50 ml) and makes it more suitable for transplantation into small children 
than into adults. Several approaches have been tested to overcome the cell dose 
issue, including newer techniques using ex-vivo expansion of cord blood units 
and the use of double cord blood units for single transplant in adults.  
UCB was also found to delay the immune reconstitution following 
transplant, which leaves patients vulnerable to infections for a longer period of 
time. But, UCB has the advantages of its easy availability, ease of harvest, and 
the reduced risk of GVHD. Furthermore, HSC from cord blood have been noted 
to have a greater proliferative capacity than adult HSC (Koh et al., 2004).  
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iii) Peripheral Blood Stem Cells 
Peripheral blood stem cells are now the most common source of stem 
cells for allogeneic HSCT. It has been known for decades that in adults, under 
steady-state conditions, the majority of HSCs reside in bone marrow and a small 
number of stem and progenitor cells circulate in the bloodstream. However, in 
the past 10 years, researchers have found that by injecting the donor with a 
cytokine, such as granulocyte-colony stimulating factor which can induce the 
progenitor cells to migrate from the bone marrow into peripheral blood in 
greater numbers. 
PBSC is preferable for donor as harvesting from peripheral blood is 
easier with minimal pain, no anesthesia, shorter period of hospital stay and 
better yields for transplants. The peripherally harvested cells contain twice as 
many HSC as stem cells taken from the bone marrow and it was also result in 
faster engraftment (Childs et al, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
2.3 PERIPHERAL BLOOD STEM CELL TRANSPLANTATION 
2.3.1 Introduction  
 Peripheral blood stem cells (PBSC) have been used for 
 transplantation since the early 1990s, and they are increasingly replacing bone 
 marrow as a source of stem cells. Peripheral blood stem cell transplants 
 (PBSCT) are procedures that restore the stem cells that have been destroyed by 
 treatment of high dose chemotherapy. Chemotherapy delivered in high doses 
 will destroy all the cancer cells but at the same time, it will also destroy the 
 stem cells that are present in the bone marrow. Therefore, PBSCT will restore 
 all the cells that have been destroyed by the chemotherapy. 
 
2.3.2 Peripheral Blood Stem Cell  Mobilization 
 It is well accepted that there is a small number of circulating 
 progenitor cells in the peripheral blood and that this number can be 
 dramatically increased by a wide variety of mobilization stimuli (Link, 2001). 
 As in adults, under steady-state,  the majority of the HSC reside in the bone 
 marrow and only a very low number is present in peripheral blood (Hong et al., 
 1994 and Stadmauer et al., 1995). However, it was noted that there was a 
 dramatic increase in the numbers of circulating early hematopoietic cells during 
 recovery from cytotoxic chemotherapy. Thus, the chemotherapeutic agents used 
 were shown to be able to mobilize stem cells (Reiffers et al., 1986, Gianni et al., 
 1989, Tavassoli, 1992 and Richman et al., 1996).  
Later, it was found that certain hematopoietic growth factor can augment 
the mobilization of circulating progenitor cells when given after chemotherapy 
(Duchrsen et al., 1988; Sheridan et al., 1992; Hong et al., 1994 and Stadmauer 
 15 
et al., 1995). Recently, growth factor alone has been found to increase the 
percentage of progenitor cells in blood. Several growth factors including 
granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony 
stimulating factor (GM-CSF), interleukin (IL) -1, IL-3, IL-8, IL-11 and stem cell 
factor (SCF)  have been shown to mobilize progenitor cells into the circulation 
(Fibbe et al., 1992; Andrew et al., 1992; Guillaume et al., 1993; Eaves, 1993; 
Peter et al., 1993; Smith, 1994; Reisner and Segall, 1995; Laterveer et al., 1995 
and Mauch et al., 1995).  
Combinations of cytokines have been studied in animals, and these early 
studies demonstrated that certain cytokines, for example G-CSF+  SCF, G-CSF 
+ GM-CSF or IL-11+SCF, may be superior to single cytokines in mobilizing 
progenitor cells into the circulation (Briddell et al., 1993; deRevel et al., 1994 
and Mauch et al.,1995). However, G-CSF is the most widely used cytokine for 
mobilization of stem cells at present (Pusic and DiPersio, 2008). Daily 
administration of G-CSF permits the PBSC harvest at day 5 after the initiation of 
the G-CSF in healthy donor. While in autologous patient setting, the use of 
chemotherapy and G-CSF, the optimal day for harvesting varied from patient to 
patient, ranging from days 10 to 15 after the initiation of chemotherapy.  
 Several factors such as long therapeutic history, prior exposure to 
 alkylating agents or radiation therapy and bone marrow infiltration had been 
 reported to affect the stem cell mobilisation negatively (Drake et al., 1997; 
 Ketterer et al., 1998 and Perea et al., 2001). 
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2.3.3 Peripheral Blood Stem Cell Harvesting  
2.3.3.1 Introduction 
Although PBSC harvest and transplantation have become routine 
procedures, more is to be known about the release of progenitor cells from the 
bone marrow into the peripheral blood. It has been shown that progenitor cells 
can be recruited into the peripheral blood during PBSC collection (Zingsem et 
al., 1992; Hillyer et al., 1993; Murea et al., 1996; Fliedner, 1998; Smolowicz et 
al., 1999; Humpe et al., 1999, Rowley et al., 2001).  PBSC are collected from 
the blood through a process known as apheresis.  
 Apheresis is a Greek word meaning taking away, which can be 
 performed by several devices available such as Cobe Spectra, Haemonetics, 
 Baxter  Amicus and Fresenius. The donor or patient blood is passed through an 
 apparatus that separates out the stem cells constituent and the remainder is 
 returned to the circulation. Centrifugation is the most common method of 
 separation and it can be divided into two types; continuous flow 
 centrifugation and intermittent flow centrifugation.  
Continuous flow centrifugation required two venous access for        
collecting and returning the blood to patient/donor. „Continuous‟ means the 
blood is collected, spun, and returned simultaneously. The main advantage of 
this system is the low extracorporeal volume used in the procedure, which is of 
benefit to the elderly and children. However, the intermittent flow centrifugation 
works in cycles, taking blood, spinning/processing it and then giving back the 
necessary parts to the  donor in a bolus. The main advantage of this is a single 
venipuncture site.  
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2.3.3.2 Principle of PBSC Harvesting (Apheresis) using COBE Spectra 
TM 
 
Apheresis System (COBE BCT, Inc., Lakewood, CO, USA) 
   
 PBSC harvesting is the procedure for collection of PBSC contained in 
the mononuclear cell layer after mobilization of stem cell into the peripheral 
circulation of autologous patients. The Cobe Spectra Apheresis System is the 
automated centrifuge based blood cell separator that provides the function 
necessary to control and monitor the  extracorporeal circuit during apheresis 
procedures. 
 The Cobe Spectra Apheresis System consists of spectra disposables and 
spectra apheresis system. Spectra disposables consists of a separation channel 
that spins in centrifuge to separate blood into it components and blood tubing 
that routes blood and replacement fluids through the system.  
 
 
Figure 4: Diagram of Disposable Set of the COBE Spectra 
TM 
Apheresis System 
  
Pre-attached Plasma Bag 
One Collect Bag 
Sterile Barrier Filters 
 RBC Reservoir 
CCM Cuvette 
 Thin Collect Line 
Red-colored 4 Lumen Connector 
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 This system uses continuous flow centrifugation type of separation. The 
 centrifugation will separate the cells to the cell layers according to cell size and 
 specific gravity as shown in Figure 5 and Figure 6.  
 
Figure 5: The Diagram Show the Layers of Cells Distributed in the Centrifuge 
of COBE Spectra Apheresis System  
 
Figure 6: The Cells Separation by Specific Gravity 
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During the apheresis procedure, the anticoagulant is automatically mixed with 
the blood as it is pumped out from the body into the apheresis machine. The 
purpose of this mixing procedure is to prevent coagulation of the blood. 
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2.4 CD34
+
 CELLS  
2.4.1 Introduction 
 The use of monoclonal antibodies against CD (cluster of differentiation) 
antigens has excellently facilitated the precise characterization of different 
haemotopoietic lineages. Monoclonal antibodies against the same antigens are 
grouped together based on the reactivity and biochemical and/or genetic 
characterization of the corresponding antigen (Schlossman et al., 1995). 
 The CD34 antigen is a family of differentially glycosylated type 1 
transmembrane single chain glycoproteins that is expressed on virtually all 
hematopoietic progenitor cells. CD34
+
 cells which represent the most immature 
1 to 4 percent of bone marrow mononuclear cells including more primitive 
haematopoietic progenitor cells and the levels of CD34
+
 cells are very low in 
unmobilized blood approximately 0.1% of total blood mononuclear cells 
(Smeland et al., 1992). 
  After mobilization with cytokines, the level of CD34
+
 cells increases 
markedly and the percentage of CD34
+
 cells in the apheresis products may 
approach the percentages in bone-marrow grafts (Siena et al., 1993; Smith, 
1994; Fielding et al., 1994 and Stadmauer et al., 1995). The CD34
+
 cell numbers 
in the peripheral blood can be used to determine the optimal time for apheresis 
and according to previous studies a cut off peripheral blood CD34
+
 cells with a 
varied range of 8 to 40 cells/ul is an indicator for stem cell harvesting (Yu et al., 
1999; Fantao et al., 1999; Heuft et al., 2000; Kudo et al., 2003 and Moncada et 
al., 2003).  
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2.4.2 CD34
+  
Cells and Engraftment 
 Several studies have shown that there is a direct relation between the 
time of engrafment and the number of CD34
+ 
cells in the apheresis product 
infused to the patient during transplant after high dose therapy. The studies 
showed that more than 2 x10
6 
CD34
+ 
cells/kg body weight of patient are needed 
for timely multilineage engraftment (Dercksen et al., 1995; Bensinger et al., 
1995 and Mavroudis et al., 1996).  Furthermore, in autologous transplantations 
using mobilized peripheral blood CD34
+ 
cells, it has been found that doses of 
CD34
+ 
cells higher than 5x10
6 
CD34
+ 
cells/kg are associated with early 
trilineage engraftment reduced  transfusion needs and shortened the hospital stay 
(Bender et al., 1992; Bensinger et al., 1995; Weaver et al., 1995 and Remes et 
al., 1997).  
 Transplantation of CD34
+ 
cells of more than 2x10
6
/kg has led to faster 
recovery than doses below 2x10
6 
CD34
+ 
cells/kg. It has also been shown that, 
the recovery of platelets often was delayed when fewer CD34
+ 
cells were 
transplanted to patients even though the recovery of neutrophil remained fast 
(Mavroudis et al., 1996), whereas in patients given doses below 1x10
6 
CD34
+ 
cells/kg, they had a higher transplantation related mortality than patients who 
received more than 1x10
6 
CD34
+ 
cells/kg (Moore, 1991). These data suggests 
that the dose of CD34
+ 
cells given to patient can predict the rate of survival post-
transplantation as well as the speed of engraftment. 
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2.4.3 Quantification of CD34 by Flow Cytometry 
2.4.3.1 Introduction  
Enumeration of CD34
+
 cells has become a reality with the development 
of monoclonal antibodies and flow cytometer.  It is possible to determine the 
percentage or absolute number of CD34
+
 cells in routine clinical use nowadays. 
Currently, the most widely used guidelines for stem cell identification is 
proposed by International Society of Hematotherapy & Graft Engineering, 
ISHAGE (Sutherland et al., 1996). 
 Cytometry is a combination of two words which are cyto meaning cell 
and metry meaning measurement. In other words, cytometry is a measurement 
of physical and chemical characteristics of cells. It allows simultaneous 
measurement of single cells at a rapid rate up to thousands of particles per 
second through an optical and electronic apparatus (Chapman, 2000).  
 
                
Figure 7: Flow Cytometer; Becton Dickinson FACSCalibur 
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2.4.3.2 Principle of Flow Cytometry 
A flow cytometer consist of three main components which are fluidics, 
optics and electronics as shown in Figure 8.  
 
Figure 8: Components of Flow Cytometer 
A beam of laser light of a single wavelength is directed onto a 
hydrodynamically-focused stream of fluid. A number of detectors are aimed at 
the point where the stream passes through the light beam: one in line with the 
light beam (Forward Scatter or FSC) and several perpendiculars to it (Side 
Scatter or SSC).  
Each suspended particle from 0.2 to 150 micrometers passing through 
the beam scatters the ray, and fluorescent chemicals found in the particle or 
attached to the particle may be excited into emitting light at a longer wavelength 
than the light source. This combination of scattered and fluorescent light is 
picked up by the detectors. Then fluctuations in brightness at each detector were 
analyzed to derive various types of information about the physical and chemical 
structure of each individual particle. FSC correlates with the cell volume and 
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SSC depends on the inner complexity of the particle such as the shape of the 
nucleus, the amount and type of cytoplasmic granules or the membrane 
roughness. 
 The process of collecting data from the flow cytometer is termed as 
„acquisition‟. Acquisition is mediated by a computer that is connected to the 
flow cytometer and the software which handles the digital interface with the 
cytometer. The software is capable of adjusting parameters such as voltage, 
compensation and threshold for the specimen being tested. The data generated 
by the flow cytometer can be plotted to produce histogram, two or three 
dimensional dot plot. The regions on this dot plot can be sequentially separated 
based on the fluorescent intensity, by creating a series of subset extraction terms 
as „gates‟ (Ormerod, 2008). Specific gating protocol exists for diagnostic and 
clinical purposes especially in hematology. 
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3.0 METHODOLOGY 
3.1 PATIENTS 
 This is a cross-sectional and retrospective study from January 2007 
 to December 2009. All autologous patients undergoing PBSC harvesting were 
 recruited. The inclusion criteria are all autologous patients who have 
 successfully undergone PBSC harvest procedures. The exclusion criteria are 
 patients who have undergone PBSC harvesting but with incomplete data and 
 those who experienced failed procedures. For this study, one patient was
 excluded because of failed procedure due to unstable condition of the patient. 
 Data were retrieved from the UKM Medical Centre Integrated 
 Laboratory Management System (ILMS) and also from the records of the Stem 
 Cell Laboratory.  
3.2  METHODS  
3.2.1 PBSC Mobilisation 
 For patients undergoing autologous PBSC harvesting, chemotherapy and 
G-CSF were given for stem cell mobilization. The use of G-CSF( Neupogen) 
continue after the initiation of chemotherapy regime, and it varied from patient 
to patient, ranging from days 10 to 15.  Once peripheral blood CD34
+  
count   
15 cells/ul,  the PBSC from patient will be harvested until achieve ≥ 2 x106 
CD34
+ 
cells/kg body weight.  
In the case of good mobilizer, PBSC harvesting will be continued until 
the collection yield achieves ≥ 5 x106 CD34+ cells/kg body weight even though 
the collection yield on day 1 had achieved 2 x10
6
 CD34
+ 
cells/kg body weight as 
high stem cell dose may be associated with improved hematopoietic recovery 
and survival in patients undergoing HSCT. In some patients, mobilization may 
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be ineffective to allow collection of this threshold dose. Poor mobilization is 
defined as collection of ≤ 2 x106 CD34+ cells/kg body weight. 
 
3.2.2 PBSC Harvesting (Apheresis) 
 All aphereses were performed using a COBE Spectra 
TM 
Apheresis 
System (COBE BCT, Inc., Lakewood, CO, USA). Stem cell collections in all 
these patients were performed with the semiautomated MNC program (software 
Version 5.1). The materials and methodology performing apheresis are as in 
Appendix I. Figure 9 shows patients during the PBSC harvesting procedure. The 
patients were connected to the apheresis machine using a femoral catheter.  
  
 
Figure 9: PBSC Harvesting Procedure 
 
 Total blood volume (TBV) processed was calculated using the COBE 
Spectra software based on sex, height and weight of the patient. The machine 
will process approximately 2x TBV of the patients. The apheresis procedure 
usually will take about three to four hours to complete and the collection volume 
ranging from 50 ml to 200ml. The length and volume of collection varied 
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between patients depending on their own TBV and also their condition 
throughout the procedure. The targeted collection yield was to achieve ≥ 2 x106 
CD34
+ 
cells/kg body weight, the minimum dose required for transplantation. 
PBSC harvesting will be performed on the next day if the stem cell yield count 
for day 1 was ≤ 2 x106 CD34+ cells/kg body weight. PBSC harvesting will 
continue until the minimum targeted doses of ≥ 2 x106 CD34+ cells/kg body 
weight is achieved. 
 
 
3.2.3 Sampling 
 
The peripheral blood for CD34
+ 
cells count taken on the day of 
harvesting is named as the „pre-apheresis peripheral blood CD34+ cells sample‟. 
Pre-apheresis samples of peripheral blood for CD34
+ 
cells analysis were drawn 
about 2 hours after G-CSF administration on the day of PBSC harvesting.  
The peripheral blood sample taken after harvesting was completed is 
named as „post-apheresis CD34+ cells count‟. The stem cell product samples of 
harvested material were taken from the collection bags after gentle mixing 
before processing, and this sample is named as the „stem cell yield‟. All these 
samples were collected into EDTA anticoagulant tubes and analyzed by flow 
cytometry within 2 hours of collection.  
The peripheral blood for CD34
+ 
cells count sent on the second day of 
harvesting is named as the „pre-apheresis peripheral blood CD34+ cells day 2‟. 
The stem cell product sample for second day harvesting is named as the „stem 
cell yield day 2‟.  If the harvesting still continue, The third day peripheral blood 
sent for CD34
+ 
cells count is named as the „pre-apheresis peripheral blood 
CD34
+ 
cells day 3‟. „Stem cell yield day 3‟ referred to the stem cell product 
sample for third day of harvesting. 
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3.2.4 CD34
+
 Cells Enumeration 
 Daily White Blood Cell (WBC) count was monitored daily before 
performing the CD34
+
 Cells Enumeration. Once WBC count was  1.0 x109/L, 
peripheral blood CD34
+ 
cells enumeration was performed daily until the 
peripheral blood CD34
+  15/ul.  The patient‟s PBSC was harvested once the 
peripheral blood CD34
+  15/ul.   
 The pre- and post-apheresis peripheral blood CD34
+ 
cells and PBSC 
product samples were stained with BD combined antibody reagents which 
consist of PE-conjugated anti-CD34 and FITC-conjugated anti-CD45 in a BD 
Trucount Tube. Exclusion of dead CD34
+
 cells from viable CD34
+
 cells 
enumeration is achieved using the 7-Amino actinomycin (7-AAD) viability Dye 
where the viable cells remain unstained (negative).  
 The materials and methods for performing CD34
+ 
cells enumeration is 
described in the Appendix II. The steps involved in CD34
+
 cells staining before 
quantification by flow cytometer is shown in Figure 10. The staining procedure 
normally takes about 30 minutes.  
 
 
 
 
 
 
 
 
Figure 10:The Diagram Showing the Steps in CD34
+
 Cells Staining  
1. The following reagent and   
    sample  was added to the     
    Trucount Tube: 
  20 ul CD34/CD45 
antibody 
 50 ul sample 
 20ul 7-AAD solution 
 
2.  Incubated for 15 minutes 
 
3.  1ml 1x Pharm Lyse was  
     added to the tube 
 
4.  Incubated for another 10  
     minutes 
 
5.  Analyzed on flow cytometer 
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3.2.5 Acquisition and Analysis of CD34
+
 Cells by Flow Cytometer 
Flow cytometric analysis of CD34
+ 
cells in pre- apheresis, post-apheresis 
peripheral blood and apheresis yield was performed by FACScalibur (Becton 
Dickinson, USA) with Becton Dickinson Stem Cell kit. The acquisition protocol 
is described in the Appendix III. The analysis is performed using the ISHAGE 
protocol for true CD34
+
 HSC criteria; 
i.   Positive CD34 expression 
ii.  Dim CD45 expression 
iii. Low to intermediate FSC 
iv. Low SSC 
 
An example of dot plot obtained after acquisition by flow cytometer is shown 
below in Figure 11(a-f). 
 
                 
 
 Figure 11(a): Plot 1; All events collected are shown in this plot. R3 defines 
 all leucocytes (lymphocytes, monocytes and granulocytes) except blue 
 coloured dots defined as beads. Region R5 defines CD45
+ 
events.  Region R8 
 defines the lymphocyte population. 
 
Plot 1 
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 Figure 11(b): Plot 2; Discrimination of live cells from dead cells. Events 
        falling in R2 (non-viable cells) were gated out from further analysis. 
 
 
 
 
 Figure 11(c): Plot 3; Gated on live CD45
+
 leukocytes. R1 defines    
  TruCOUNT beads. R4 defines as bright CD34
+
 events. 
 
 
 
Plot 3 
Plot 2 
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Figure 11(d): Plot 4; R5 defines clustering of live CD45
+ 
and CD34
+
 events 
 
 
 
    
 
Figure 11(e): Plot 5; Live lymphocytes and monocytes. The left side of R6 
 is drawn to include cells no smaller than lymphocytes. 
 
 
 
Plot 5 
Plot 4 
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        Figure 11(f): Plot 6; Region R7 defines the TruCOUNT beads 
 
3.3 Statistical Analysis 
 The statistical analysis for this study was carried out using Statistical Package 
 for Social Science (SPSS) software version 18 and MedCalc Statistic for 
 Biomedical Research version 11 for windows.  
 
  3.3.1 Data Analysis 
 a) The following equation was used for calculation of collection efficiency: 
         Total CD34
+
 cells in Apheresis Product   x   100 
   Pre-apheresis  Post-apheresis      x      Total Blood  
   CD34
+
 cells        +    CD34
+
 cells        Processed 
        2 
b) Correlation study using Pearson Correlation analysis between: 
i) pre-apheresis peripheral blood CD34+ cells and stem cell yield 
ii) day 1 post-apheresis peripheral blood CD34+ cells and day 2 pre-
apheresis peripheral blood CD34
+
 cells  
iii) day 1 post-apheresis peripheral blood CD34+ cells and day 2 stem 
cell yield  
Plot 6 
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c) Receiver Operating Characteristic (ROC) Curve Analysis was used to 
 determine the cut-off point of pre-apheresis peripheral blood CD34
+
 cells 
 to achieve sufficient stem cell yield of  2 x106/ kg body weight for 
 PBSCT. 
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4.0 RESULTS 
 4.1 PATIENT DEMOGRAPHY 
A) A total of 94 PBSC harvesting procedures have been performed for 48 
patients (30 men and 18 women). These patients were diagnosed with non-
Hodgkin‟s Lymphoma, NHL (n=24), Acute Myeloid Leukemia, AML (n=12), 
Multiple Myeloma, MM (n=8), and Hodgkin‟s Lymphoma (n=4). NHL cases 
include Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), 
Waldenström's macroglobulinemia,  Mediastinal NHL,  Burkitt‟s Lymphoma,  
Mantle Cell Lymphoma, Primary Lung Lymphoma and Richter's Transformation 
of Chronic Lymphocytic Leukaemia (CLL). The median age is 58 years old 
(range 14-67) and the age ranges for the different disease groups are as shown in 
Table 1. The male:female ratio is 1.7:1 and the median body weight was 58 kg 
(range 34.6 – 101 kg).  
Table 1: Characteristics of Patients (for age and weight, in range)  
  NHL AML MM 
HODGKIN’S 
LYMPHOMA TOTAL 
NO OF PATIENTS 24 12 8 4 48 
MALE 20 4 5 1 30 
FEMALE 4 8 3 3 18 
AGE (RANGE) 17-67 14-51 40-63 26-29 14-67 
PATIENT'S BODY 
WEIGHT, KG (RANGE) 
34.6-94 44-64 58-101 38-65 34.6 - 101 
 
 
B) For the peripheral blood stem cell harvesting the minimal targeted stem 
cell yield of CD34
+
 cells is  2x106 per kg recipient body weight. The median 
number of apheresis procedures per patient was 2 (range, 1-3) in which 13 
patients have undergone one apheresis, 24 patients with two procedures and the 
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remaining 11 patients with three apheresis procedures with the intention to 
collect a sufficient amount of CD34
+
 cells for transplantation.  
 
C) These patients have been treated with the standard chemotherapy 
regimens and were in remission or minimal residual disease state. These patients 
were mobilized with chemotherapy and G-CSF (neupogen). 43/48 patients 
(89.6%) managed to produce CD34
+
 cells yield of  2 x106/ kg body weight 
with 3 or less apheresis procedures. 34/48 (70.8%) of these patients achieved 
this minimal targeted yield with only one apheresis procedure, 9/48 patients 
(18.8%) with two procedures. The remaining 5 patients failed to obtained the 
stem cell yield of 2 x10
6
/kg body weight. 16/48 patients (33.3%) were able to 
achieved CD34
+
 cells collection yield of  5 x106/ kg body weight in one 
harvesting procedure.  
 
Table 2: Apheresis Yield of CD34
+
 Cell 
 
  
 
 
 
  
 
 
 
 
CD34
+
 Cells Yield No of patients 
 2 x106/ kg body weight 43 
              With one apheresis 34 
              With two apheresis 9 
≤ 2 x106/ kg body weight 5 
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4.2 PRE-APHERESIS BLOOD CELL COUNT AND COLLECTION 
 CHARACTERISTIC 
The characteristics of pre- apheresis blood cell count and the collection 
yield are shown in Table 3. The median WBC pre-apheresis was 19.5 x10
9
/L 
(range 2.0-71.3 x10
9
/L) and the median percentage of lymphocyte and monocyte 
were 4.5% and 6.7% with ranges (1.0-33.1% and 0.3-39.5%) respectively.  
The median pre-apheresis peripheral blood CD34
+
 cells were 33.6/ul 
(9.5-456.5/ul). For the PBSC harvesting procedures using Cobe Spectra 
performed with the semiautomated MNC program (software Version 5.1), an 
estimate of 2x total blood volume were processed. In these patients, the median 
blood volume processed was 8701 ml (range 4583 – 12918 ml), and the median 
PBSC volume collected was 153.5 ml (40-246 ml).  
 The median CD34
+
 cells collected was 2.6x10
6
 /kg body weight, with the 
range 0.1 x10
6
 /kg - 32.5 x10
6
 /kg. Following the harvesting, the median post 
apheresis peripheral blood CD34
+
 cells was 28.5/ul (range 3.58/ul - 240.5/ul) 
which was about 15% lower compared to pre-apheresis CD34
+ 
 count.  
Table 3: Pre-Apheresis Blood Cell Count and Collection Characteristic 
  Median Range 
White Blood Cell (WBC) Count, x10
9
/L 19.5 2.0-71.3 
Pre-harvest Lymphocyte count, % 4.5 1.0 - 33.1 
Pre-harvest Monocyte count, % 6.7 0.3 - 39.5 
Pre-apheresis Peripheral Blood CD34
+
 Cells/ul  33.6 9.5 - 456.5 
Post-apheresis Peripheral Blood CD34
+ 
Cells/ul  28.5  3.58 - 240.5 
Total CD34+ Cells Yield, x10
6
/ kg body weight 2.6 0.1 - 32.5 
Total Blood Volume Processed, ml 8701 4583 - 12918 
Total Collection Volume, ml 153.5 40 - 246 
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4.3 CORRELATION STUDY  
4.3.1 Pre-apheresis Peripheral Blood CD34
+
 Cells and Product Yield  
  The correlation study between pre-apheresis peripheral blood CD34
+
 
 cells and product yield using Pearson‟s Correlation analysis based on paired 
 samples from 94 apheresis for day 1 to day 3 of apheresis procedures (Figure 
 12(a) has shown a positive correlation with r = 0.963.  Based on all the 94 
 apheresis procedures, a cut off value of  33 cells/ul pre-apheresis peripheral 
 blood CD34
+
 cells count may predict a stem cell yield of  2 x106 CD34+ cells/ 
 kg body weight (r = 0.963, p < 0.001).       
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Figure 12(a): Correlation Analysis of Overall Pre-Apheresis Peripheral Blood 
CD34
+
 Cells and Stem Cell Yield for Day 1, 2 and 3 PBSC Harvesting 
Stem Cell Yield (x10
6
 CD34
+
 cells/ kg body weight)   
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4
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l) R=0.963 
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Figure 12(b): Correlation Analysis of Pre-apheresis Peripheral Blood 
CD34
+
 Cells and Stem Cell Yield for Day 1 PBSC Harvesting 
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 Figure 12(c): Correlation Analysis of Pre-apheresis Peripheral Blood 
 CD34
+
 Cells and Stem Cell Yield for Day 2 Harvesting 
R=0.967 
 Stem Cell Yield (x106 CD34+ cells/ kg body weight)   
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  Figure 12(d): Correlation Analysis of Pre-apheresis Peripheral Blood 
  CD34
+
 Cells and Stem Cell Yield for Day 3 Harvesting 
 
In Figure 12 (b-d), pre-apheresis peripheral blood CD34
+
 cells for day 1, 2 and 3 
correlated well with the respective stem cell yield for each day with r value of  
0.967 (day 1), 0.913 (day 2) and 0.939 (day 3).  In these correlation study, they 
showed that to predict the stem cell yield of   2 x106 CD34+ cells/ kg body 
weight with single apheresis, the pre-apheresis peripheral blood CD34
+
 cells 
count should be ≥ 28 cells/ul, and to achieve the yield of   5 x106 CD34+ cells/ 
kg body weight, the pre-apheresis peripheral blood CD34
+
 cells count of  ≥ 70 
cells/ul should be obtained. Whereas for day 2 and day 3 PBSC harvesting, the 
cut off value of peripheral blood CD34
+
 cells count to achieve the stem cell yield 
of  2 x106 CD34+ cells/ kg body weight was approximately 35 cells/ul. 
   
 Stem Cell Yield (x106 CD34+ cells/ kg body weight)   
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4.3.2 Post-apheresis Peripheral Blood CD34
+
 Cells Day 1 and Day 2 Pre-
 apheresis Peripheral Blood CD34
+
 Cells   
 The correlation between post-apheresis peripheral blood CD34
+
 cells day 
1 PBSC harvesting and pre-apheresis peripheral blood CD34
+
 cells day 2 
showed that there is a positive correlation between this two variables with the r 
value of 0.895, which means that the higher post-apheresis peripheral blood 
CD34
+
 cells count day 1 predicted a higher count of day 2 pre-apheresis 
peripheral blood CD34
+
 cells (r = 0.895, p < 0.001). Figure 13 showed a cut off 
value of  ≥ 25 cells/ul post-apheresis peripheral blood CD34+ cells count day 1 
correlated with a 35/ul CD34
+
cells for day 2 pre-apheresis peripheral blood.  
Referring to Figure 12 (c), to predict a day 2 stem cell yield of  2 x106 CD34+ 
cells/ kg body weight, a day 2 pre-apheresis peripheral blood CD34
+
 cells count 
of 35/ul should be considered. 
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Figure 13: Correlation Analysis of Post-Apheresis Peripheral Blood CD34
+
 
Cells Day 1 and Day 2 Pre-Apheresis Peripheral Blood CD34
+
 Cells  
R = 0.895 
Day 2 Pre-apheresis Peripheral Blood CD34
+
 cells (/ul)  
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4.3.3 Post-apheresis Peripheral Blood CD34
+
 Cells Day 1 and Day 2 Stem Cell 
 Yield  
 Further analysis was carried out to determine a correlation between post-
apheresis peripheral blood CD34
+
 cells day 1 PBSC harvesting and day 2 stem 
cell yield in the 28 apheresis procedures (Figure 14). In this analysis, 7 apheresis 
procedures were excluded due to incomplete data. The scatter dot plot showed 
that post-apheresis peripheral blood CD34
+
 cells day 1 PBSC harvesting 
correlated well with day 2 stem cell yield cells ( r = 0.811, p < 0.001). A cut off 
value of 25 cells/ul post-apheresis peripheral blood CD34
+
 cells count day 1 
correlated well with the stem cell yield day 2 with r value of 0.811 though 
slightly lower as compared to day 2 pre-apheresis peripheral blood CD34
+
 cells 
and stem cell yield day 2 with r = 0.913.  
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Figure 14: Correlation Analysis of Post-apheresis Peripheral Blood CD34
+
 
Cells Day 1 and Day 2 Stem Cell Yield  
R = 0.811 
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In terms of the number of procedures achieving stem cell yield of   2 x106 
CD34
+
 cells/kg body weight with cut off values of 25 cells/ul day 1 post-
apheresis and 35 cells/ul day 2 post-apheresis were 17 and 16 respectively.  
 With these results, day 1 post-apheresis peripheral blood CD34
+
 cells 
count may be used to predict the day 2 stem cell yield without performing a day 
2 pre-apheresis peripheral blood CD34
+
 cells count which is time consuming 
and may delay the PBSC harvesting procedures. 
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4.4 RECEIVER OPERATING CHARACTERISTIC CURVE ANALYSIS 
 The Receiver Operating Characteristic (ROC) curve analysis was used to 
evaluate the cut-off value of pre-apheresis peripheral blood CD34
+
 cells to 
achieve the stem yield of  2 x106 CD34+ cells/ kg body weight. Data from 94 
apheresis for day 1 to day 3 of apheresis procedures were analyzed. Based on all 
the 94 apheresis procedures, a cut off (or criterion) value of > 27 cells/ul pre-
apheresis peripheral blood CD34
+
 cells count was the value with the highest 
average of sensitivity (95%) and specificity (82.4%) that may predict a stem cell 
yield of   2 x106 CD34+ cells/ kg body weight. Figure 15(a). 
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Figure 15(a): ROC Curve of Overall Pre-Apheresis Peripheral Blood CD34
+
 
Cells and Stem Cell Yield for Day 1, 2 and 3 PBSC Harvesting 
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Table 4(a): Criterion Values and Coordinates of the ROC Curve for Day 1, 2 
          and 3 PBSC Harvesting 
 
 
 
 Analysis from overall data showed an area of 0.935 under the ROC curve. 
This means that a randomly selected individual from the positive group (stem 
cell yield  2 x106 CD34+ cells/ kg body weight)  has a test value larger than that 
for a randomly chosen individual from the negative group (stem cell yield ≤ 2 
x10
6
 CD34
+
 cells/ kg body weight)  in 93.5% of the time. Area under the ROC 
curve (AUC) also lies with 95% confidence interval and was significantly 
different between the two groups (P <0.0001).    
            In Figure 15 (b-d), ROC curve showed a cut off value of pre-apheresis 
peripheral blood CD34
+
 cells for day 1, 2 and 3 with the respective stem cell 
yield for each day with AUC of  0.895 (day 1), 0.969 (day 2) and 0.9 (day 3). 
All the data was significantly different with p value <0.001. For day 1, ROC 
curve analysis showed that to predict the stem cell yield of   2 x106 CD34+ 
cells/ kg body weight with single apheresis, the pre-apheresis peripheral blood 
CD34
+
 cells count should be ≥ 27 cells/ul. Whereas for day 2 and day 3 PBSC 
harvesting, the cut off value of peripheral blood CD34
+
 cells count to achieve 
Area under the ROC curve (AUC)  0.935 
Standard Error 
a
 0.0248 
95% Confidence Interval 
b
 0.864 to 0.975 
z statistic  17.501 
Significance level P (Area=0.5) <0.0001 
 
a
 Hanley & McNeil, 1982 
 
b
 Binomial exact 
 
  
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>27 * 95 86.1 - 99.0 82.35 65.5 - 93.2 5.38 0.061 90.5 90.3 
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the stem cell yield of  2 x106 CD34+ cells/ kg body weight was 26.5 cells/ul 
and  ≥ 27 cells/ul respectively.  
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Figure 15(b): ROC Curve of Pre-apheresis Peripheral Blood CD34
+
 Cells and 
               Stem Cell Yield for Day 1 Harvesting 
 
Table 4(b): Criterion Values and Coordinates of the ROC Curve for Day 1  
           PBSC Harvesting 
 
 
 
 
 
 
 
 
 
Area under the ROC curve (AUC)  0.895 
Standard Error 
a
 0.0451 
95% Confidence Interval 
b
 0.772 to 0.965 
z statistic  8.767 
Significance level P (Area=0.5) <0.0001 
 
a
 Hanley & McNeil, 1982  
 
b
 Binomial exact  
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>27 * 94.12 80.3 - 99.3 71.43 41.9 - 91.6 3.29 0.082 88.9 83.3 
 
Sensitivity: 94.1 
Specificity: 71.4 
Criterion:  >27 
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Figure 15(c): ROC Curve of Pre-apheresis Peripheral Blood CD34
+
 Cells and 
               Stem Cell Yield for Day 2 Harvesting 
 
Table 4(c): Criterion Values and Coordinates of the ROC Curve for Day 2  
           PBSC Harvesting 
 
 
 
 
 
 
 
 
Area under the ROC curve (AUC)  0.969 
Standard Error 
a
 0.0284 
95% Confidence Interval 
b
 0.848 to 0.999 
z statistic  16.525 
Significance level P (Area=0.5) <0.0001 
 
a
 Hanley & McNeil, 1982  
 
b
 Binomial exact  
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>26.5 * 95.24 76.2 - 99.9 92.86 66.1 - 99.8 13.33 0.051 95.2 92.9 
 
 
Sensitivity: 95.3 
Specificity: 92.9 
Criterion:  >26.5 
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Figure 15(d): ROC Curve of Pre-apheresis Peripheral Blood CD34
+
 Cells and 
   Stem Cell Yield for Day 3 Harvesting 
 
Table 4(d): Criterion Values and Coordinates of the ROC Curve for Day 3  
           PBSC Harvesting 
  
Area under the ROC curve (AUC)  0.9 
Standard Error 
a
 0.106 
95% Confidence Interval 
b
 0.576 to 0.997 
z statistic  3.78 
Significance level P (Area=0.5) 0.0002 
 
a
 Hanley & McNeil, 1982  
 
b
 Binomial exact  
 
 
 
 
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>27 * 100 47.8 - 100.0 83.33 35.9 - 99.6 6 0 83.3 100 
 
Sensitivity: 100 
Specificity: 83.4 
Criterion:  >27 
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4.5 COLLECTION EFFICIENCY 
 A total of 77 apheresis data had been analyzed for collection efficiency 
of CD34
+
 cells using Cobe Spectra Apheresis Machine with semiautomated 
MNC program. Calculation of collection efficiency for 17 apheresis could not be 
performed due to incomplete variables. The variables that are needed in the 
calculation of collection efficiency are total CD34
+
 cells in apheresis product, 
pre-apheresis peripheral blood CD34
+
 cells, post-apheresis peripheral blood 
CD34+ cells and total blood volume processed. 
 The following formula was used for the calculation of collection 
efficiency;  
         Total CD34
+
 cells in Apheresis Product   x   100 
   Pre-apheresis  Post-apheresis      x      Total Blood  
   CD34
+
 cells        +    CD34
+
 cells        Processed 
        2 
 
The median values and range for all parameters that influenced the percentage of 
collection efficiency are shown in Table 5. The median overall collection 
efficiency of CD34
+
 cells was 63.7%. This collection efficiency is comparable to 
the manufacturer‟s data which is in the range of 55-65%. 
Table 5: Collection Efficiency and Contributing Variables 
  Median Range 
Pre-apheresis Peripheral Blood CD34
+
 
Cells/ul  
33.6 9.5 - 456.5 
Post-apheresis Peripheral Blood CD34
+
 
Cells/ul  
28.5  3.58 - 240.5 
Total CD34+ Cells Yield, x10
6
 137.7 4.4 - 2567 
Total Blood Volume Processed, ml 8701 
4583 - 
12918 
Collection Efficiency, % 63.7 5.5 – 116.2 
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5.0 DISCUSSION 
 A major challenge in PBSC harvesting from mobilized patients is to 
collect a sufficient number of CD34
+
 cells for transplantation and the 
requirements are different between institutions. In UKM Medical Centre, a 
minimum amount of 2 x10
6
 CD34
+
 cells/kg body weight recipient is used. This 
study was performed on 48 patients with haematological diseases. 
 In the current practice, PBSC harvesting will be performed when the pre-
apheresis peripheral blood CD34
+
 cells count achieved 15cells/ul. From the 
analysis, 43 patients (89.6%) were successful and 5 patients (10.4%) failed to 
obtain stem cell yield of 2 x10
6
/ kg body weight with 3 or less apheresis 
procedures. Only 34 patients (70.8%) achieved  2 x106/ kg body weight with 
one apheresis procedures.  
 In this study, the pre-apheresis peripheral blood CD34
+
 cell count and 
product yield has shown a significant positive correlation with r = 0.963 and         
p < 0.001. The cut-off value of 33 cells/ul pre-apheresis peripheral blood CD34
+
 
cells count has shown to predict a stem cell yield of  2 x106 CD34+ cells/kg 
body weight (r = 0.963, p < 0.001).  
 Meanwhile, the data also been evaluated for cut-off point using Receiver 
Operating Characteristic (ROC) curve analysis. Based on all the 94 apheresis 
procedures, a cut off (or criterion) value of > 27 cells/ul pre-apheresis peripheral 
blood CD34
+
 cells count was the value with the highest average of sensitivity 
and specificity that may predict a stem cell yield of   2 x106 CD34+ cells/ kg 
body weight. Both methods of evaluation showed different cut-off value. 
However, the use of ROC analysis was more appropriate statistical method 
when evaluating the cut-off values for clinical intervention.  
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 ROC curve analysis was used to compare the diagnostic performance of 
two or more laboratory or diagnostic tests (Griner et al., 1981). The ability of a 
test to discriminate diseased cases from normal cases also can be evaluated 
using ROC curve analysis (Metz, 1978; Zweig and Campbell,1993). In 
determining the cut-off (or criterion) value, rarely there will be a perfect 
separation between the two groups. Indeed, the distribution of the test results 
will overlap. In ROC curve analysis, the criterion value selected had the highest 
average of sensitivity and specificity.  
 In a ROC curve, the true positive rate (Sensitivity) is plotted in function 
of the false positive rate (100-Specificity) for different cut-off points. Each point 
on the ROC plot represents a sensitivity/specificity pair corresponding to a 
particular decision threshold. A test with perfect discrimination (no overlap in 
the two distributions) has a ROC plot that passes through the upper left corner 
(100% sensitivity, 100% specificity). The closer the ROC plot is to the upper left 
corner, the higher the overall accuracy of the test (Zweig and Campbell, 1993). 
 Therefore, a cut-off value of 27 cells/ul instead of 33 cells/ul pre-
apheresis peripheral blood CD34
+
 cell count could be implemented in order to 
get a minimum dose of  2 x106 CD34+ cells/ kg body weight in most patients. 
This result is comparable to the study done by Alessandro et al., 2005. They 
found that a value  66/μl was associated with a higher probability of collecting 
 4 × 106 /kg CD34+ cells, which is considered the optimal target for an 
autologous support after high-dose therapy.  
 Besides that, Heuft et al., 2000 has concluded that pre-apheresis 
peripheral blood CD34
+
 cell count  40/ul is highly predictive of a single PBSC 
apheresis product with more than  2.5 × 10
6
 /kg CD34+ cells. Not only that, the 
recommendations for the level of pre-apheresis peripheral blood CD34
+
 cells 
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count that should be used to initiate apheresis has varied from 8 to 20/ul (Yu et 
al., 1999; Fantao et al., 1999; Kudo et al., 2003 and Moncada et al., 2003). If 
harvesting is initiated at a lower pre-apheresis peripheral blood CD34
+
 cells 
count, daily yield will be lower and more apheresis procedures are required to 
achieve an adequate harvest. If the target is set too high for the pre-apheresis 
peripheral blood CD34
+
 cells count, only few patients will reach the targeted 
count or the peak of mobilisation may be missed in some heavily pre-treated 
patients.  
 Although the logic for having a target setting for pre-apheresis CD34
+
 
cells count was to avoid the inefficiency and cost of collections with poor yields, 
this also result in the exclusion of a number of patients from PBSC harvest and 
eventually from transplantation. Therefore, Gidron et al., 2008 propose a 
formula to facilitate the decision of PBSC harvesting if performing apheresis 
whenever there are any circulating CD34
+
 cells is an approach of practice. By 
collecting a small numbers of stem cells over several harvest, this may afford 
these patients an opportunity to undergo transplantation. 
 However, by using this approach or an absolute threshold as guideline 
before performing PBSC harvesting does not give 100% guaranteed result as 
there were also other factors that may affect the stem cell yield.  Patient's age, 
diagnosis, preceding chemoradiotherapy, disease invasion of the bone marrow 
and mobilizing chemotherapy and cytokines, timing for apheresis, machines and 
operating software, length and volume of collection would affect the yield in 
PBSC collection for autologous transplants. 
 The present study also showed that there is a significant positive 
correlation between day 1 post-apheresis peripheral blood CD34
+
 cells and day 2 
pre-apheresis peripheral blood CD34
+
 cells (r = 0.895, p < 0.001), and it also 
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correlated well with day 2 stem cell yield ( r = 0.811, p < 0.001). A cut off value 
of  ≥ 25 cells/ul post-apheresis peripheral blood CD34+ cell count may be used 
to predict the day 2 stem cell yield of  2 x106 CD34+ cells/kg body weight 
without performing a day 2 pre-apheresis peripheral blood CD34
+
 cell count. 
 Therefore, PBSC harvesting procedure for the day 2 can be performed 
without waiting for the result of peripheral blood CD34
+
 cells count of the day 
which may delay the second day apheresis procedure, thus leading to late 
processing and cryopreservation of stem cell products. Besides, by doing the day 
1 post-apheresis peripheral blood CD34
+
 cells count which parellel with the 
count of stem cell yield day 1, this may also save manpower as well as the 
reagent costs.    
 Up to this point of time, no previous studies could be found on either the 
correlation between day 1 post-apheresis peripheral blood CD34
+
 cells count and 
day 2 pre-apheresis peripheral blood CD34
+
 cell count or the correlation 
between day 1 post-apheresis peripheral blood CD34
+
 cells count and day 2 stem 
cell yield.   
 The collection of PBSC can be performed on various cell separator 
devices and in this study, the collection efficiency (CE) was evaluated on the 
Cobe Spectra apheresis machine using semiautomated MNC program. The 
median overall CE of CD34
+
 cells was 63.7% with a range of (5.5% – 116.2%) 
and this value is comparable to the manufacturer‟s data which is in the range of 
55-65%. The calculation of CE are dependent on the variables as in the 
following equation;   
 
         Total CD34
+
 cells in Apheresis Product   x   100 
   Pre-apheresis  Post-apheresis      x      Total Blood  
   CD34
+
 cells        +    CD34
+
 cells        Processed 
        2 
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 In other words, CE is equal to stem cell yield divided by total quantity of 
cells processed (TQproc) through the channel during the procedure. The 
calculation for the TQproc is influenced by the % change in the CD34
+
 count 
during the procedure. The post-apheresis peripheral blood CD34
+
 count is 
usually lower than the pre-apheresis peripheral blood CD34
+ 
count, and the 
average fall may range from 0% to – 60% or more and in the present study, the 
median % change was 15% from pre-apheresis peripheral blood to post-
apheresis peripheral blood count. 
 The % change in CD34
+ 
count from the pre-apheresis procedure value is 
primarily an indication of cell mobilization during the procedure.  A 0% fall in 
the count suggests that a lot of cells have been mobilized; an 80% reduction in 
the post-apheresis count suggests few cells were mobilized.  This influences the 
calculation of the quantity of cells that were processed through the channel, and 
thereby influences the calculations of CE.  The CE for 0% in pre/post count 
yields a low CE while the CE for –80% fall in pre/post -apheresis counts yields a 
higher CE. The following variables have been observed to influence the 
percentage of CE;  
i) CE is inversely related to the % change in the pre/post CD34+ 
count.  That is, the greater the drop in the CD34
+ 
count, post 
procedure, the higher the CE.  This is an indirect reflection of cell 
mobilization during the procedure. The greater the mobilization, 
the less the fall in the count, and the lower the CE. The 
magnitude of mobilization is a biological factor over that could 
not be predicted.   Inefficient device separation and collection 
such as poor interface positioning for collection and device 
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inefficiency, could result in a smaller % decease in the CD34
+  
count 
ii) CE is positively correlated with the CD34+ yield, when the yield 
is expressed as some % of the starting quantity of CD34
+ 
 
available in the peripheral blood to be collected, a product of the 
pre-apheresis count x donor blood volume. Procedures may 
collect less than 100% of the initial CD34 quantity, but in well-
performed procedures that process 2 and 3x the blood volume, 
the yield will be some value above 100% of the starting quantity  
iii) The CE is also associated with the total blood volume (TBV) 
processed. TBV processed was calculated using the COBE 
Spectra software based on the sex, height and weight of the 
patient. In these patients, the median TBV processed was 8701 
ml (range 4583 – 12918 ml). High TBV processed will result in 
low CE. For example if  3 x TBV processed, the CE falls unless 
the yield rises above 180% of the starting quantity.   
 
 Therefore, the lower or higher value of CE is very subjective in 
determining the efficiency of the apheresis machine as this value is also 
dependent on the mobilization process throughout the PBSC harvesting 
procedure. It is possible that the CE was low because of the post-apheresis count 
is high due to mobilization, which makes it look like the machine did not 
perform an efficient PBSC collection. 
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6.0 CONCLUSION 
 In summary, this study has shown a significant positive correlation 
between pre-apheresis peripheral blood CD34
+
 cells and stem cell yield. A cut-
off value of 27 cells/ul pre-apheresis peripheral blood CD34
+
 cells count may be 
used to predict stem cell yield of  2 x106 CD34+ cells/kg body weight. By 
doing this, the number of apheresis with poor stem cell yield may be reduced 
and this may help to reduce the wastage of consumables, man power, costs and 
numbers of PBSC harvesting procedure.  
 Furthermore, the day 1 post-apheresis peripheral blood CD34
+
 cell count 
with a value of ≥ 25 cells/ul may be used to predict the day 2 stem cell yield of  
 2 x106 CD34+ cells/kg body weight without performing a day 2 pre-apheresis 
peripheral blood CD34
+
 cells count which may delay the PBSC harvesting 
procedure and thus the stem cell processing procedure.  
 Overall, the median CE of CD34
+
 cells was 63.7% and this value is 
comparable to the manufacturer‟s data which is in the range of 55-65%. The 
value of CE is very subjective in determining the efficiency of the apheresis 
machine or a particular apheresis protocol as this value also dependent on the 
mobilization process of patients that is difficult to measure throughout the PBSC 
harvesting procedure.  
 In conclusion, the product yield and collection efficiency of                            
peripheral blood stem cell harvesting can be estimated using peripheral blood 
CD34
+
 cells quantification. The results obtained may serve as a guide to 
improve the PBSC harvesting procedure in UKM Medical Centre and shed new 
light on the the survival rate post-transplantation as well as the speed of 
engraftment. 
 
 56 
BIBLIOGRAPHY 
 
Alessandro, C., Marzia, V., silvia, M., Patricia, Z., Catherine, K., Chiara, R., Emile C., 
Angela, L., Daniela, T., Erica, C. and Mario, L. (2005). Bone marrow CD 34+ cell 
count is predictive for adequate peripheral progenitor cell collection. Leukemia 
Research 29: 159-163. 
 
Andrews, R.G., Bensinger, W. and Knitter, G. (1992). The ligand for c-kit  stem cell 
factor, stimulates  the circulation of cells that  engraft  lethally  irradiated baboons.  
Blood  80: 920-927 .  
 
Barker, J.N. and Wagner, J.E. (2003). Umbilical cord blood transplantation: current 
practice and future innovations. Crit Rev Oncol Hematol. 48: 35-43.  
 
Bender, J. G., To, L. B., Williams, S., Schwartzberg, L. S. (1992). Defining a 
therapeutic dose of peripheral blood stem cells. J Hematother 1: 329-341. 
 
Bensinger, W., Appelbaum, F., Rowley, S., Storb, R., Sanders, J., Lilleby, K., Gooley, 
T., Demirer, T., Schiffman, K,, Weaver, C., Clift, R., Chauncey, T., Klarnet, J., 
Montgometry, P., Petersdoft, S., Weiden, P., Witherspoon, R., Buckner, C. D. (1995) 
Factors that influence collection and engraftment of autologous peripheral-blood stem 
cells. J Clin Oncol 13:2547-2555. 
 
Beyer, J., Schwella, N., Zingsem, J., Strohscher, I., Schwaner, I., Oettle, H., Serke, S., 
Huhn, D. W. (1995). Hematopoietic rescue after high-dose chemotheraphy using 
autologous peripheral-blood progenitor cells or bone marrow: A randomize 
comparison. J Clin Oncol 13:1328-1335. 
 
Briddell, R. A., Hartley, C.A., Smidt, K.A. and Mcniece, I. K. (1993).  Recombinant  
rat stem cell factor  synergizes  with  recombinant  human granulocyte  colony –
stimulating factor  in  vivo in mice to mobilize peripheral blood and  progenitor  cells 
that  have enhance repopulating potential. Blood 82: 1720-1723.  
 
Bruno, B., Rotta, M., and Patriarca, F. (2007). A comparison of allografting with 
autografting for newly diagnosed myeloma. N Engl J Med 356 (11): 1110-1120 
 
Canellos and George (1997). The Role of Salvage Therapy in Malignant Lymphomas. 
The Oncologist 2(3): 181-183. 
 
Chapman, G.V. (2000). Instrumentation for flow Cytometry. Journal of Immunological 
Methods, 243:2-12 
 
Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, 
E.J., Tisdale, J., Dunbar, C., Linehan, W.M., Young, N.S., and Barrett, A.J. (2000). 
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic 
peripheral-blood stem-cell transplantation. N Engl J Med 343: 750-758.  
 
Cutler C and Antin JH (2001). Peripheral blood stem cells for allogeneic 
transplantation: a review. Stem Cells 19 (2): 108-117 
 
 57 
Dercksen, M. W., Rodenhuis, S., Dirkson, M. K. A. (1995). Subsets of CD34+ cells and 
rapid  hematopoietic recovery  after peripheral blood  stem cell  transplantation.  J Clin  
Oncol  13: 1922-1932. 
 
deRevel, T., Appelbaum, F. and  Storb, R. (1994). Effects of granulocyte  colony-
stimulating  factor and stem cell factor, alone and in combination, on the mobilization  
of peripheral blood cells that  engraft  lethally  irradiated dogs. Blood 83: 3795-3799.  
 
Domen, J. and Weissman, I.L. (1999). Self-renewal, differentiation or death: regulation 
and manipulation of hematopoietic stem cell fate. Mol. Med. Today 5: 201-208.  
 
Drake, M., Ranaghan, L. and Morris, T.C.M. (1997). Analysis of the effects of prior 
therapy on progenitor cell yield: use of a chemotherapy score system. Br J Haematol 98: 
745-749.  
 
Duhrsen, U., Villeval, J.L. and  Boyd, J.  (1988). Effects of  recombinant  granulocyte  
colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 
72: 2074-2081. 
 
Eaves, C. (1993). Peripheral blood stem cells reach new heights. Blood 82:1957- 1959. 
 
Fibbe,W.,  Hamilton, M. and Laterveer, L. (1992 ). Sustained  engrafment  of mice 
transplantanted with  IL- 1  primed  blood- derived stem cells. Immunol 148: 417-421. 
 
Fielding, A.K., Watts, M.J. and Goldstone, A.H. (1994). Peripheral blood progenitor  
cells versus  bone  marrow. J  Hematother  3: 203-211.  
 
Fliedner, T.M. (1998). The role of blood stem cells in hematopoietic cell renewal. Stem 
Cells 16: 361-374. 
 
Fontao Wendel, R., Lazar, A., Melges, S., Altobeli, C. and Wendel, S. (1999) The 
absolute number of circulating CD34+ cells as the best predictor of peripheral 
hematopoietic stem cell yield. J Hematother 8: 255-262.  
 
Fruehauf, S., Haas, R. and Conradt, C. (1995). Peripheral blood progenitor cell (PBPC) 
counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC 
after Filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 85: 2619-
2626.  
 
Gianni,  A.M., Sietra, S. and Bregni, M.(1989). Rapid and  complete hematopoietic 
reconstruction following combined  transplantation of autologous blood and bone 
marrow cells. A changing role  for high dose chemo- radiotherapy?  Hematol  Oncol 7: 
139-148.  
 
Gidron, A., Singh, V., Egan, E. and Mehta, J. (2008). Significance of low peripheral 
blood CD34þ cell numbers prior to leukapheresis: what should the threshold required 
for apheresis be? Bone Marrow Transplantation 42: 439-442. 
 
Griner, P.F., Mayewski, R.J., Mushlin, A.I., and Greenland, P. (1981). Selection and 
interpretation of diagnostic tests and procedures. Annals of Internal Medicine 94: 555-
600. 
 
 58 
Guillaume, T., d‟ Hodt, V., Symann, M. (1993). IL-3 and peripheral blood stem cell 
harvesting. Stem cells 11:173-181. 
 
Hanley, J.A. and McNeil, B.J. (1982). The meaning and use of the area under a 
receiver operating characteristic (ROC) curve. Radiology 143: 29-36. 
 
Heuft, H. G. Dubiel, M., Oertel, J. De Reys, S. Rick, O. Serke, S. and Schwella, N. 
(2000). Automated collection of peripheral blood stem cells with the Cobe Spectra for 
autotransplantation. Vox Sang 79: 94-99. 
 
Hillyer, C.D., Swenson, R.B. and Hart, K.K.(1993). Peripheral blood stem cell 
acquisition by large-volume leukapheresis in growth factor-stimulated and unstimulated 
rhesus monkeys: development of an animal model. Exp Hematol 21: 1455-1459. 
 
Holtzer, H. (1978). Cell lineages, stem cells and the „quantal' cell cycle concept. In: 
Stem cells and tissue homeostasis. Eds: B.I. Lord, C.S. Potten, and R.J. Cole. 
(Cambridge, New York: Cambridge University Press). 1-28. 
 
Hong, D.S. and Deeg, H.J.(1994) . Hematopoietic  stem cells: sources and applications. 
Med Onco 11: 63-68. 
 
Humpe, A., Riggert, J., and Munzel, U. (1999). A prospective, randomized, sequential, 
crossover trial of large-volume versus normal-volume leukapheresis procedures: effect 
on progenitor cells and engraftment. Transfusion 39: 1120-1127. 
 
Joanna, E. G., Emanuela, B. and Diane, S. K. (2004). Plasticity of Bone Marrow–
Derived Stem Cells. Stem Cells 22:487-500 
 
Ketterer,  N.,  Salles, G. and Moullet, I. (1998).  Factors associated with successful 
mobilization of peripheral blood progenitor cells in 200 patients with lymphoid 
malignancies. Br J Haematol 103: 235-242.  
 
Koh, L.P. and Chao, N.J. (2004). Umbilical cord blood transplantation in adults using 
myeloablative and nonmyeloablative preparative regimens. Biol Blood Marrow 
Transplant. Vol 10:1-22.  
 
Kudo, Y., Minegishi, M., Saito, N., Itoh, T., Fushimi, J. And Takahashi, H. (2003). The 
absolute number of peripheral blood CD34+ cells predicts a timing for apheresis and 
progenitor cell yield in patients with hematologic malignancies and solid tumors. 
Tohoku J Exp Med 199: 111-118.   
 
Leblond, C.P. (1964). Classification of cell populations on the basis of their 
proliferative behavior. National Cancer Institute. 14: 119-150. 
 
Leterveer, L., Lindley, I., Hamilton, M. (1995). Interleukin-8 induces rapid mobilization  
of hematopoietic stem cells  with radioactive capacity and long-term myeloid 
repopulating ability. Blood 85: 2269-2275. 
 
Liliane, S. M., Andre, N. M., Roseli, D. L., Vicente, O. F. and Marcelo K. Z. (2001). A 
virtual reality simulator for bone marow harvest for pediatric transplant. Medicine 
Meets Virtual Reality 293-302. 
 
 59 
Link, D.C. (2001). Mechanisms of granulocyte-colony stimulating factor induced  
hematopoietic progenitor cell mobilization. Semin Hematol 37 (Suppl. 2): 25-32. 
 
Mauch, P., Lamont, C., Neben, T.Y. (1995). Hematopoietic stem cells in the blood  
after stem cell factor, and interleukin-11 administration: Evidence for different  
mechanisms of mobilization. Blood  86: 4674-4680.  
 
Mavroudis,  D., Read, E.,  Cottler-fox,  M. (1996). CD34 cell  dose predicts survival, 
posttransplant  morbidity, and rate of hematopoietic recovery after  allogenic marrow 
transplants  for hematologic  malignancies. Blood 88: 3223-3229. 
 
Metz, C.E. (1978). Basic principles of ROC analysis. Seminars in Nuclear Medicine. 8: 
283-298. 
 
Moncada, V., Bolan, C., Yau, Y.Y. and Leitman, S.F. (2003). Analysis of PBPC cell 
yields during large-volume leukapheresis of subjects with a poor mobilization response 
to filgrastim. Transfusion 43: 495-501.  
 
Moore, M. A. (1991).  Clinical implications of positive and negative hematopoietic  
stem cell regulators . Blood 78: 1-19 
 
Murea, S., Goldschmidt, H. and Hahn, U. (1996). Successful collection and 
transplantation of peripheral blood stem cells in cancer patients using large-volume 
leukaphereses. J Clin Apheresis 11: 185-194. 
 
Ormerod, M.G. (2008). Flow Cytometry – a basic introduction. ISBN 978-0955981203 
 
Osma, M.M., Ortuño, F. and de Arriba, F. (1998). Bone marrow steady-state 
CD34+/CD71− cell content is a predictive value of rG-CSF-mobilized CD34+ cells. 
Blood 21: 983-985. 
 
Perea, G., Sureda, A. and Martino, R. (2001). Predictive factors for a successful 
mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 80: 
592-597.  
 
Peters, W.P.,  Rosner, G.,  and Ross, M. (1993).  Comparative  effects of   Granulocyte-
macrophage colony – stimulating  factor ( GM- CSF)  and granulocyte colony- 
stimulating factor ( G- CSF)  on  priming  peripheral  blood progenitor cells for use 
with autologous bone marrow  after high-dose  chemotherapy. Blood 81: 1709-1719. 
 
Preston, S.L., Alison, M.R., Forbes, and S.J. (2003). The new stem cell biology: 
something for everyone. J Clin Pathol: Mol Pathol 56: 86-96 
 
Pusic, I and DiPersio, J.F (2008). The Use of Growth Factors in Hematopoietic Stem 
Cell Transplantation. Current Pharmaceutical Design 14: 1950-1961 
 
Reiffers, J., Bernard, P. and  David, B. (1986). A  successful autologous transplantation 
with peripheral  blood hematopoietic cells  in patient with acute leukemia. Exp Hematol 
14: 312-15. 
 
Reisner, Y. and Segall,  H. (1995).   Hematopoietic stem cell transplantation  for cancer 
therapy.  Curr Opin Immunol 7: 687-693.  
 60 
Remes, K., Matinlauri, I., Grenman, S., Itala, M., Kauppila, M., Pellinniemi, T.T., 
Salminen, E., Vanharanta, R., Rajamaki, A. (1997). Daily measurement of blood 
CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant 
platelet recovery. J Hematother 6:13-19. 
 
Richman, C.M., Weiner, R.S., and Yankee, R.A. (1996). Increase  in circulating stem 
cell following chemotherapy  in man. Blood  4:1031-1039. 
 
Rick, O., Beyer, J. and Kingreen, D. (2000). Successful autologous bone marrow rescue 
in patients who failed peripheral blood stem cell mobilization. Ann Hematol 79: 681-
686. 
 
Rowley, S.D., Yu, J., and Gooley, T. (2001). Trafficking of CD34+ cells into the 
peripheral circulation during collection of peripheral blood stem cells by apheresis. 
Bone Marrow Transplant 28: 649-656. 
 
Russell, N., Bessell, E., Stainer, C., Haynes, A., Das-Gupta, E., Byrne, J. (2000). 
Allogeneic haemopoietic stem cell transplantation for multiple myeloma or plasma cell 
leukaemia using fractionated total body radiation and high-dose melphalan 
conditioning. Acta Oncol 39 (7): 837-41.  
 
Schlossman, S. E., Boumsell, L., Gilks, W. (1995). Leucocyte typing V. White cell 
Differentiation Antigens.  Volume 2.  Proceeding  of 5
th
  internationnal  Workshop  and 
Conference, Boston. Oxford:  Oxford  University Press. 
 
Sheridan,  W.P., Bergley, C.G. and Juttner, C.A. ( 1992). Effect of  peripheral - blood  
progenitor  cells mobilized by filgrastim  (G. CSF) on  platelet  recovery after  high-
dose  chemotherapy. Lancet 339:640-644.  
 
Siena, S,, Bregni, M.,  Gianni, M,A. (1993).  Estimation of peripheral  blood CD34+ 
cells  for autologous  transplantation in cancer patients. Exp Hematol 21: 203-205. 
 
Smeland, E. B., Funderud, S., and Kvalheim, G. (1992). Isolation and characterization 
of human hematopoietic progenitor cells: An effective method for positive selection of 
CD34+ cells. Leukemia 6: 845-52 
 
Smith, A.M .( 1994). Peripheral blood progenitor cell  transplantation: Clinical, 
practical, and  economic  considerations. J Hematol 3: 331-348. 
 
Smolowicz, A.G., Villman, K., Berlin, G. and Tidefelt, U. (1999). Kinetics of peripheral 
blood stem cell harvest during a single apheresis. Transfusion 39: 403-409. 
 
Stadmauer, E.A., Schneider, C.J. and Silberstein, L.E. (1995). Peripheral blood 
progenitor cell generation and harvesting. Semin  Oncol 22: 291-300. 
Sutherland, D.R., Michael, K. and Gratama, Jan. W. (1996). Enumeration of CD34+ 
Hematopoietic Stem and Progenitor Cells. J Hematother 5:213  
 
Tavassoli,  M .( 1992)  . The role of conditioning  regimens in homing of transplanted  
hematopoietic cells. Bone Marrow Transplant 10: 15-17. 
 
 61 
Terese, W. (2001). In Stem Cells: Scientific progress and future research directions. 
5:44 
 
Thomas, E.D., Lochte, H.L., Lu, W.C. and Joseph, W.F.(1957). Intravenous infusion of 
bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 157: 491-
496 
 
Thomson, J.A., Itskovitz-Eldor, J. and Shapiro, S.S. (1998). Embryonic stem cell lines 
derived from human blastocysts. Science 282:1145-1147.  
 
Weaver, C.H., Hazelton, B., Birch, R., Palmer, P., Allen, C., Schwartzberg, L., West, W. 
(1995). An analysis of engraftment kinetics as a function of the CD34 content of 
peripheral blood progenitor cell collections in 692 patients after the administration of 
myeloablative chemotherapy. Blood 86:3961-3969. 
 
Weissman, I.L. (2000). Stem cells: units of development, units of regeneration, and 
units in evolution. Cell 100: 157-168. 
 
Yu, J., Leisenring, W., Bensinger, W.I., Holmberg, L.A. and Rowley, S.D. (1999). The 
predictive value of white cell or CD34+ cell count in the peripheral blood for timing 
apheresis and maximizing yield. Transfusion 39: 442-450.   
 
Zingsem, J., Zeiler, T. and Weisbach, V. (1992). PBSC collection in patients using the 
FRESENIUS-AS 104 Leucollection protocol. Int J Cell Cloning 10 (Suppl. 1): 85-87. 
 
Zweig, M.H. and Campbell, G. (1993). Receiver-operating characteristic (ROC) plots: 
a fundamental evaluation tool in clinical medicine. Clinical Chemistry 39: 561-577. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 62 
APPENDIX I 
 
MATERIALS AND METHODOLOGY FOR PBSC HARVESTING 
 
Instruments: 
 
1. The COBE Spectra TM  Apheresis System 
2. Tubing Heat Sealer 
3. Hemostats 
4. Tubing stripper 
 
Consumables and Reagents: 
 
1. AutoPBSC disposable set 
2. One return line needle or catheter  
3. Anti-coagulant (ACD-A) 
4. 0.9% NaCl for injection (1000 ml) 
 
 
Method: 
 
1.0 SET UP 
 
1.1      Equipment Set Up 
 1.1.1 Plug system into electrical outlet, as needed. 
 1.1.2 Turn power switch ON. 
  
1.2 Setting up the Disposable Tubing Set 
1.2.1 Install the standard dual-stage filler in the centrifuge, if necessary. 
Ensure that the filler in the machine is the standard dual-stage       
filler. 
 
1.3 Installing Tubing on Front Panel 
 1.3.1 Install the collect flow path overlay on the front panel. 
 1.3.2 Remove the disposable package cover and record the lot number 
  from the cover label onto the apheresis procedure record. 
 1.3.3 Remove the inlet coil, remove the tapes, and hang on left side of 
  machine. 
 1.3.4 Place the access saline line over top of machine. 
 1.3.5 Remove the return coil, remove the tape, and hang on the left side 
  of the machine. 
 1.3.6 Place the return saline spike over the top of the machine. 
 1.3.7 Remove the bags and place them in the correct position on the IV 
  pole.  
 1.3.8 Remove the return pump cartridge and snap it into the cartridge 
  clamp between the plasma and collect/replace pumps. 
 1.3.9 Remove the access pump cartridge and snap it into the cartridge 
  clamp between the AC and the inlet pumps. 
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 1.3.10 Place the AC line over the top of the machine. 
 1.3.11 Press the CONTINUE key to load the tubing into the pump  
  housings. Verify that all four pumps are loaded. 
 1.3.12 Place the lines in the collect/replace and plasma valves. 
 1.3.13 Place the return pressure sensor in the return pressure sensor 
  housing. 
 1.3.14 Install the cuvette into the collect concentration  monitor housing. 
  Take care not to touch the cuvette with your fingers. The cuvette 
  will move freely on the collect line. Push downward and turn the 
  CCM clockwise to lock into place. 
 1.3.15 Place the RBC line into the RBC valve. Ensure that the line is 
  completely inserted into the RBC detector. 
 1.3.16 Position the return and inlet air chambers in the air detectors with 
  the air chamber filters below the air detector housings. The RBC 
  Reservoir sits freely on the front panel of the Spectra system. 
 1.3.17 Place the waste lines into the waste valve assembly. 
 1.3.18 Place the line in the centrifuge pressure sensor using a “flossing” 
  action. 
 1.3.19 Place the access pressure sensor in the access pressure sensor 
  housing. 
 1.3.20 Position the return line in the return valve so that the line runs 
  horizontally through the center of the valve. 
 
1.4 Installing Channel In Centrifuge 
 1.4.1 Press the UNLOCK COVER key. 
 1.4.2 Open the centrifuge by sliding the centrifuge cover back and 
  lowering the door. 
 1.4.3 Gently extend the tubing leading to the centrifuge loop to full 
  length to ensure that the tubing is not twisted. 
 1.4.4 Fold the centrifuge channel in half and load by inserting the 
  channel through the loading port and pulling through from the top. 
 1.4.5 Position the channel in the correct orientation above the filler 
  slots before placing the centrifuge collar into the collar holder. 
 1.4.6 Load the centrifuge collar into the centrifuge collar holder,  
  closing the cover over the collar. 
 1.4.7 Lower the filler latch into the locked position. 
 1.4.8 Press the channel into position. 
 1.4.9 Press the tubes into the appropriate slots in the filler. 
 1.4.10 Place the lower bearing in the lower bearing holder, making sure 
  that the hard plastic bearing is securely seated in the bearing 
  holder. 
 1.4.11 Place the upper bearing in the upper bearing holder, making sure 
  that the hard plastic bearing is securely seated in the bearing 
  holder. 
 1.4.12 Place the upper collar into the upper collar holder. 
 1.4.13 Place the multi-lumen tubing in the exit slot on the right side of 
  the system using a “flossing” action. 
 1.4.14 Rotate the centrifuge clockwise several times to ensure that the 
  tubing does not twist and stays in place. 
 1.4.15 Close the centrifuge door and cover. 
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1.5 Priming the Disposable Tubing Set 
 1.5.1 Check the needle luer connections to make sure that they are 
  secure. 
 1.5.2 Press the “3” key to select WBC when prompted to select set 
  type. Press ENTER. 
 1.5.3 Close the white pinch clamps on the access and return lines. 
  Close the roller clamps on both saline lines. The spike leading to 
  the AC container is orange. 
 1.5.4 Press the CONTINUE key. 
 1.5.5 Connect the AC line with the orange spike to the AC container 
  and place in the AC level detector. 
 1.5.6 Connect the access and return saline lines to the saline container. 
  Press the CONTINUE key. 
 1.5.7 Open the roller clamps on the two saline lines. Press the  
  CONTINUE key to prime the disposable set. 
 1.5.8 When prompted, prime the access and return patient connections 
  by opening the white pinch clamps near the needle or luer  
  connections. 
 1.5.9 Close the access saline line, clamp the access line and press the 
  CONTINUE key to test the ration. 
 
2.0. ALARM TEST 
 
 2.1 Press the CONTINUE key to clear the warning from the screen. 
 2.2 Press the YES key to perform the alarm tests and the NO key to 
 bypass the alarm tests and the NO key to bypass the alarm tests. 
 If the NO key is selected, you may proceed to Enter 
 Donor/Patient Data. 
 2.3 Ensure that the access saline is closed and the access and return 
 lines are clamped. Press the CONTINUE key. The COBE Spectra 
 System will test the access pressure sensor low alarm and the air 
 in return chamber alarm. 
 2.4 At the prompt, open the roller clamp on the access saline lines. 
2.5 Press the CONTINUE key. The Cobe Spectra System will test the 
 return pressure high alarm and the air in return chamber alarm. 
 2.6 At the prompt, verify that the return line valve is closed. Press the 
 CONTINUE key to go on to the next test. 
 2.7 Press the UNLOCK COVER key and open the centrifuge door to 
 perform the fluid leak detector alarm test. 
 2.8 Touch the fluid leak detector with your fingers to initiate the 
 alarm. Verify that the COBE Spectra System indicates that fluid 
 is detected in the centrifuge. 
 2.9 Close the centrifuge door and cover. Press the continue key. 
 
 
3.0  ENTER DONOR/PATIENT DATA 
 
 3.1 Enter the donor/patient sex. Press ENTER. 
 3.2 Enter the donor/patient height. Press ENTER. 
 3.3 Enter the donor/patient weight. Press ENTER. 
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 3.4 Respond to the Total Blood Volume display. Pressing the Yes 
  key accepts the data and the NO key redisplays the data for  
  collection. 
 3.5 Enter the hematocrit as a whole number. Press the ENTER key. 
 3.6 Enter the pre-procedure WBC concentration. Press ENTER. A 
  WBC count and MNC differential from the day of collection are 
  preferred. The system will not accept the zero default. You must 
  enter a number here. 
 3.7 Enter the MNC percentage. Press ENTER. The system will not 
  accept the zero default if no plasma is desired. 
 3.8 Pressing the Yes key approves the values. Pressing the NO key 
  prompts the operator to change a value.  
 
 
4.0  CONNECT DONOR/PATIENT 
 
 4.1 Perform the venipunctures for the access and return needle sites 
  or connect a catheter. If performing a venipuncture, the return 
  needle selected by the facility should be connected to the luer on 
  the return site to maintain extended storage capability if closed 
  system is desired. 
 4.2 Open the white pinch clamps on the return line to keep the return 
  needle from clotting. 
 4.3 Leave a saline drip on the return line to keep the return needle 
  from clotting. 
 4.4 Close the roller clamp on the access saline line. 
 
 
5.0  RUN MODE 
 
 5.1 Press the CONTINUE key to initiate the run Mode. 
 5.2 When prompted, close the return saline roller clamp. 
 5.3 Press the CLEAR key to remove the message about closing the 
  return saline from the screen. The system will first establish the 
  interface, then proceed with the run.  
 5.4 When prompted, press the “1” key to initiate Rinseback. 
 5.5 If an alarm message is received during the procedure, the  
  operator should consult the Troubleshooting section of the  
  Operator‟s Manual and follow the instructions for that alarm. 
 
 
6.0  RINSEBACK 
 
 6.1 Close the white pinch clamp on the access line and open the 
  access saline line. 
 6.2 Press the CONTINUE key to begin Rinseback. 
 6.3 Remove/disconnect the access needle and place in an appropriate 
  biohazard container. 
 6.4 Clamp and disconnect the collection bags when prompted. Press 
  the CLEAR key. Both the product and the plasma bags should be 
  permanently sealed. 
 
 66 
7.0  DISCONNECT DONOR OR PATIENT/ UNLOAD PUMPS 
 
 7.1 When the Rinseback mode is completed, close the white pinch 
  clamp on the return line. Remove/ disconnect the return needle 
  and place in an appropriate biohazard container, The donor /  
  patient must be disconnected before unloading the pumps. 
 7.2 Close the roller clamps on the access and the return saline lines. 
 7.3 Press the continue key. Record final values. 
 7.4 Press the CONTINUE key to unload pumps. The inlet pump will 
  run to verify that the lines are closed. 
 
 
8.0  REMOVING THE DISPOSABLE SET 
 
 8.1 Place the access and return connections in an appropriate  
  biohazard disposable container. 
 8.2 Press the UNLOCK COVER key and open the centrifuge. 
 8.3 Remove the multi-lumen tubing from the exit slot on the right 
  side of the system. 
 8.4 Remove the upper collar from the upper collar holder. 
 8.5 Remove the upper bearing from the upper bearing holder. 
 8.6 Remove the lower bearing from the lower bearing holder. 
  push the filler latching pin toward the center of the centrifuge and 
  raise the filler latch. 
 8.7 Remove the tubes from the slots in the filler. 
 8.8 Remove the channel from the filler. 
 8.9 Remove the centrifuge collar. 
 8.10 Raise the channel above the filler. 
 8.11 Fold the channel in half and lower through the loading port. 
  Remove form centrifuge compartment. 
 8.12 Close the centrifuge door and cover. 
 8.13 Remove the lines from the front panel, including: collect and 
  plasma valves, return pressure sensor, waste divert valve, RBC 
  line valve, CCM, return and inlet air detectors, centrifuge  
  pressure sensor, access pressure sensor, return line valve, AC 
  level detector. 
 8.14 Remove the pump cartridges from the cartridges clamps. 
 8.15 Remove the fluid containers and waste bag from the pole and 
  dispose of the disposable set in a biohazard bin. 
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APPENDIX II 
 
MATERIALS AND METHODOLOGY FOR CD34
+ 
CELLS ENUMERATION  
 
Instruments: 
 
1. Flow cytometer (FacsCalibur, Becton Dickinson) 
2. Vortex 
 
 
Disposable items: 
 
1. Trucount tube (Becton Dickinson) 
2. Pipettes  
3. Pipette tips 
 
 
Samples and Reagents: 
 
1. BD combined antibody reagent CD34/CD45 (Becton Dickinson) 
2. 7-AAD Solution (Becton Dickinson) 
3. PharM Lyse reagent (Becton Dickinson) 
4. BD Stem Cell Control Sample (Becton Dickinson) 
5. Phosphate-buffered saline (PBS, Gibco) 
 
 
Method: 
 
1) Specimen Collection & Preparation 
 
 All samples were kept at room temperature until staining. 
 
 The correct anti-coagulant for different sample types were used for example 
PBSC / mobilized PBSC use EDTA tube. 
 
 All samples were stain within 8 hours of collection. 
 
 Stained sample were acquired within 2 hours of staining. 
 
 Dilution was to be done with 1X PBS for WBC count is ≥50x103/uL.  
 
 Smearing of blood down the side of the tube have to be avoided because if blood 
remains on the side of the tube, it will not be stained but can be picked up by the 
lysing solution. 
 
 
2) Staining Method  
 
 The steps for performing the staining of CD34+ cells as shown in Figure 10. 
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3) Instrument Set Up: 
 
1. Machine calibration was performed by using BD Calibrite 3 beads with 
FACSComp software. All the parameters have to pass the calibration. 
 
2. The calibration steps as follow; 
 
 
 
Figure 16: The Flow Cytometer Calibration Step 
 
3. Assay Selection : Lyse/No Wash method. 
 
4.   Example of calibration result 
 
 
Figure 17: Example of Calibration Result 
1
st
 Tube Label: U 
 
1ml Sheath Fluid 
+ 
1 drop unlabelled beads 
1. Prepare 2 tubes: 
U M 
2
nd
 Tube Label: M 
 
3ml Sheath Fluid 
+ 
1 drop unlabelled beads 
+ 
1 drop FITC  beads 
+ 
1 drop PE beads 
+ 
1 drop PerCP beads 
 2. Select Assays 
    - Lyse/No wash (LNW) 
 
3. Run 
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 4). Acquisition Set Up: 
 
 
 Launching CellQuest Pro software by double clicking the “CD34 
ISHAGE template”. 
 
 Choose <Connect to Cytometer > from the <Acquire> menu. 
 
 
 
 The Acquisition view of the Browser appears: 
 
 
 
 Identify the location for FCS file storage during acquisition: 
 
 Key in the sample ID & patient ID. 
 
 Apply the optimized instrument setting 
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5). Acquisition 
 
 Place the sample in Sample Injection Port in flow cytometer and 
click <run> with <low> mode. 
 
 Click to select the <Setup> box in <Acquisition Control> window. 
Select “Acquire”. 
 
 Check the subpopulations from the dot plots. Make sure all the 
subpopulations are in scale. Increase FL1 threshold to exclude 
unwanted debris. 
 
 If satisfied with the setting, click “Pause” _ “Abort” _Deselect the 
“Setup”. For actual acquisition, click “Acquire”. 
 
 Change the flow rate to “High”. 
 
The life-gate is used to collect  ≥ 75,000 CD45 EVENTS. 
 
                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Figure 18: Example of Result After Acquisition  
 
[Type a quote from the document or the summary of an 
interesting point. You can position the text box anywhere in the 
document. Use the Text Box Tools tab to change the formatting of 
the pull quote text box.] 
[Type a quote from the document or the summary of an 
interesting point. You can position the text box anywhere in the 
document. Use the Text Box Tools tab to change the formatting of 
the pull quote text box.] 
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6) Data analysis  
 The CD34+ cell count is using this formula; 
 =    # CD34
+
 events     X     TruCount Beads       X     Dilution factor 
        # Beads events             Blood volume (50uL) 
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APPENDIX III 
 
Table 6: RAW DATA OF PATIENT 
 
No Patient’s ID 
Harvest 
Date 
Age Sex 
Weight 
(kg) 
Disease 
1 N007209 01/03/07 28 F 45 Hodgkin's Lymphoma 
2 N063986 01/09/07 45 F 52 Follicular Lymphoma 
3 N098229 01/15/07 67 M 62 DLBCL 
4 N102705 01/29/07 17 M 51 AML  
5 N102713 03/05/07 45 M 44 AML 
6 N098229 03/19/07 67 M 62 DLBCL 
7 N107407 04/23/07 56 M 64 AML  
8 N116876 05/07/07 58 M 73 DLBCL 
9 N088027 06/11/07 39 F 48 AML  
10 N104139 07/02/07 49 F 58 Multiple Myeloma 
11 N128071 07/09/07 51 M 64 AML  
12 N114544 08/03/07 63 M 63 DLBCL 
13 N105997 08/09/07 17 F 34.6 Mediastinal NHL 
14 N114544 08/25/07 63 M 66 DLBCL 
15 M711767 09/04/07 46 F 54 AML  
16 N136142 09/11/07 58 M 67 DLBCL 
17 N140139 09/12/07 49 F 58 Multiple Myeloma 
18 N113689 09/24/07 46 M 94 DLBCL 
19 N140116 10/01/07 40 F 55 Multiple Myeloma 
20 N049871 12/10/07 42 M 63 Multiple Myeloma 
21 N167349 01/07/08 41 F 51 AML 
22 M791130 01/21/08 54 M 61 Multiple Myeloma 
23 N176296 01/28/08 50 M 68 DLBCL 
24 N106564 02/11/08 31 M 79 DLBCL 
25 N182038 10/3/208 26 F 45 Hodgkin's Lymphoma 
26 N143357 03/12/08 14 F 47 AML 
27 N032451 03/28/08 33 M 80 
Waldenström's 
macroglobulinemia 
28 N143357 04/15/08 14 F 47 AML 
29 N168579 04/23/08 51 F 54 AML  
30 N168579 06/11/08 51 F 54 AML  
31 N184220 07/21/08 21 M 70 Burkitt’s Lymphoma 
32 N214557 10/28/08 45 M 48 DLBCL 
33 N173722 10/29/08 26 M 78 NHL 
34 N211185 11/03/08 57 M 60 DLBCL 
35 N214081 12/29/08 48 F 44 AML 
36 N172910 01/13/09 24 M 53 NHL 
37 N218398 01/20/09 29 M 65 Hodgkin's Lymphoma 
38 M001071 02/19/09 61 M 69 Richter's Transformation of CLL 
39 N083268 03/09/09 28 F 49 DLBCL 
40 N211483 04/20/09 59 M 101 Multiple Myeloma  
41 M955006 04/29/09 27 F 38 Hodgkin's Lymphoma 
42 M837505 05/04/09 42 F 58 Mantle Cell Lymphoma 
43 M924781 05/26/09 22 M 72.5 Primary Lung Lymphoma 
44 N246502 06/11/09 46 M 51 DLBCL 
45 M237724 07/05/09 63 M 58 Multiple Myeloma 
46 N248310 07/26/09 37 M 73 DLBCL 
47 N239635 11/05/09 53 M 73 Multiple Myeloma 
48 M727727 12/16/09 47 M 44 Follicular Lymphoma 
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No 
Patient’s ID 
WBC 
count 
Pre-
apheresis 
Peripheral 
Blood  
Day 1 
Total 
CD34+ 
Cells   
Day 1 
(x106)  
Stem Cell 
Yield  
Day 1 
(x106/kg 
Body 
Weight) 
Post-
apheresis 
Peripheral 
Blood  Day 1 
Total 
Blood 
Volume 
Process 
Volume 
(ml) 
Lymph 
% 
Mono 
% 
1 N007209 29.4 65.9 184 4.09   7186 60 1.9 4.4 
2 N063986 10.8 32.7 144 2.77   7139 91 4.2 10.1 
3 N098229 19.6 30 124 2   9284 141 6 39.5 
4 N102705 71.3 116.4 295 5.9   8667 171 2.1 17.4 
5 N102713 31.5 14.9 4.4 0.1   8013 40 5.4 2.7 
6 N098229 18.7 22 62 1   8859 141 6 6.8 
7 N107407 56.2 30 135 2.11   9482 246 2.4 2.6 
8 N116876 15.3 24.5 109.5 1.5 22 9425 153 9.2 17.3 
9 N088027 11.7 13 48 1 7.5 6613 61 8.2 33 
10 N104139 14.9 58 229.6 3.96 49 7264 181 5.2 22.9 
11 N128071 22 40 115.2 1.8 28.5 9858 80 12.4 4.7 
12 N114544 18.5 27 39.6 0.6 27.5 9073 81 5.9 19.7 
13 N105997 10.9 23 38 1   6097 122 1.6 25.1 
14 N114544 11.6 19 151.8 2.3 26 9953 169 10.3 11.9 
15 M711767 7.7 24 124.2 2.3 26.5 7729 156 4.8 24.2 
16 N136142 5.6 29.5 53.6 0.8 24 9150 50 33.1 13.9 
17 N140139 6 37 145 2.5 53.5 9500 91 7.6 2.8 
18 N113689 30.4 256.5 1101 12.7 156 11861 175 3.7 0.5 
19 N140116 18.2 159 552.7 10   8100 159 5.8 1.3 
20 N049871 37.2 371 1814.4 28.8 144 9801 221 8 2.2 
21 N167349 11.9 51.5 112.2 2.2 38 8571 80 4.8 2 
22 M791130 14.1 123.5 719.8 11.8 77 10033 183 4.9 3.9 
23 N176296 2 58.5 319.6 4.7 83 9592 81 24.4 18.7 
24 N106564 40.7 456.5 2567 32.5 236.5 11156 201 4.7 3.1 
25 N182038 26.1 330 940.5 20.9 240.5 7052 80 3.3 4.4 
26 N143357 7.1 32.8 38.2 0.8 23.7 7042 80 19 5.2 
27 N032451 8.8 40.5 224 2.8 29.5 11015 172 1.9 7.1 
28 N143357 6.7 9.5 19.12 0.4 15 6483 80 7.6 16 
29 N168579 6.5 33.7 145.8 2.7 23.6 9588 235 13.4 22.2 
30 N168579 15.6 28 156.8 2.9 34 7254 162 3 15.8 
31 N184220 5.8 32 224 3.2 71.1 8991 161 11.7 6.6 
32 N214557 11.5 75 432.22 9 75 8632 182 1 1.6 
33 N173722 12.8 114 650.72 8.3 71.5 10010 177 16 26.4 
34 N211185 31.3 194 856.37 14.2 97.1 10001 190 2.8 6.2 
35 N214081 19.8 29.3 129.04 2.9 13.5 6507 159 3.5 1.4 
36 N172910 11.6 29.8 140.3 2.6 18.2 10114 195 12.4 0.5 
37 N218398 9.5 59 403.1 6.2 65.4 9908 182 1.7 5.5 
38 M001071 10.1 28 161.4 2.3 23.2 10233 133 2 2.9 
39 N083268 42.1 94 397 8.1 50.3 7303 159 4.4 29.2 
40 N211483 8.3 132 1184 11.7 98.4 12918 215 8.1 3.4 
41 M955006 14.7 73.4 286 7.5 48.3 7001 155 2.1 0.8 
42 M837505 24.6 20.7 86.9 1.4 11.4 8512 168 9.2 7.8 
43 M924781 5.1 42.1 32.8 0.5 64.9 11157 102 6.5 16.4 
44 N246502 15.4 17.2 98.6 1.9 9.1 10847 204 7.5 15.2 
45 M237724 3.1 65.5 568.4 9.8 81 10003 191 14.8 6.7 
46 N248310 10.3 49 452 6.2 40.4 8701 157 8.2 2.3 
47 N239635 35.3 16.9 88.3 1.2 6 8337 163 9.4 7.1 
48 M727727 17.7 32 123.1 2.8 19.5 7502 161 3.7 1.3 
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No Patient’s ID 
WBC 
count 
Pre-
apheresis 
Peripheral 
Blood  
Day 2 
Total 
CD34+ 
Cells 
Day 2 
(x106)  
Stem Cell 
Yield   
Day 2 
(x106/kg 
Body 
Weight) 
Post-
apheresis 
Peripheral 
Blood Day 2 
Total 
Blood 
Volume 
Process 
Volume 
(ml) 
Lymph 
 % 
Mono 
% 
1 N007209 52.6 54.10 130.5 2.9   7411 80 1.7 4.5 
2 N063986 20.1 51.20 114.4 2.2   7352 100 2.6 29.3 
3 N098229 28.2 15.50 62 1   9938 90 3.2 0.7 
4 N102705                   
5 N102713 54.2 10.50 22 0.5     144 3.2 20.2 
6 N098229 24.7 10.90 24.8 0.4   9995 61 2.7 4.3 
7 N107407 51.2 22.80 97.2 1.52   9263 156 1.9 2.5 
8 N116876 31 22.00 62.7 0.88   9133 154 4 7.2 
9 N088027 15.6 25.00 107.5 2.24 21.5 7032 72 9 12.3 
10 N104139 24.5 76.50 150.8 2.6 49 7313 100 5.4 0.3 
11 N128071 42 26.50 12.8 0.2 25 9158 70 2.3 2.1 
12 N114544 23.7 11.60 13.2 0.2 5.4 9705 111 11.1 4.1 
13 N105997 21.2 12.00 30.4 0.8 11.7 6000 120 1.5 8.9 
14 N114544 31 29.00 126 2 13 7024 125 6 1 
15 M711767 21.6 55.50 180.9 3.35 47 7206 163 2.2 2.3 
16 N136142 12.6 40.00 167.5 2.5 29 10020 170 14.2 10.2 
17 N140139 17.3 89.00 362.5 6.25 77 9518 150 3.1 1.9 
18 N113689                   
19 N140116                   
20 N049871                   
21 N167349 24.5 64.50 173.4 3.4 33.5 8553 102 2 31.8 
22 M791130                   
23 N176296                   
24 N106564                   
25 N182038                   
26 N143357 10.7 46.00 38.2 0.8 14 6363 80 11.2 7.4 
27 N032451 10 41.50 256 3.2 40 11052 100 2 2.5 
28 N143357 19.2 17.00 76.48 1.6 20.5 6308 164 3.1 10.1 
29 N168579 16.5 64.50 156.8 2.9 29.4 7243 167 5.1 7.6 
30 N168579 15 48.00 221.4 4.1 37 7092 179 2.4 17.8 
31 N184220 16.5 95.80 347.2 4.9 70 10898 168 3.9 11.6 
32 N214557                   
33 N173722                   
34 N211185                   
35 N214081 20.3 25.5 28.42 0.5 20.2 5736 62 4.5 7.4 
36 N172910 12.9 28.50 162.9 3 11.6 9374 174 10.8 26.1 
37 N218398                   
38 M001071 19.7 51.00 179.4 2.6 31.2 10234 146 3 5.2 
39 N083268 33 41.00 162 3.3 17.4 7309 151 2.2 25.4 
40 N211483                   
41 M955006 38.1 81.00 239 6.3 64.5 4583 104 1.9 0.9 
42 M837505 26.4 21.30 37.8 0.65 15.3 9320 206 8.4 18.6 
43 M924781 11.2 100.00 551 7.6 67.8 12015 186 2.2 5.4 
44 N246502 25.7 14.00 43.2 0.8 3.58 11031 202 4.2 25.6 
45 M237724 14.8 156.90 661 11.4 113.3 6982 136 3.2 1.7 
46 N248310 19.4 74.00 379 5.2 54.4 11003 196 4.5 1.7 
47 N239635 28.9 16.00 75.9 1 8.11 8581 166 9 5.3 
48 M727727 21.5 34.00 194 4.4 24.9 7357 187 2.4 2 
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No Patient’s ID 
WBC 
count 
Pre-
apheresis 
Peripheral 
Blood  
Day 3 
Total 
CD34+ 
Cells 
Day 3 
(x106)  
Stem Cell 
Yield  
Day 3  
(x106/kg 
Body 
Weight) 
Post-
apheresis 
Peripheral 
Blood Day 3 
Total 
Blood 
Volume 
Process 
Volume 
(ml) 
Lymph 
 % 
Mono 
% 
1 N007209                   
2 N063986                   
3 N098229                   
4 N102705                   
5 N102713                   
6 N098229                   
7 N107407 105.4 10.7 19.2 0.3 9.2 6359 70 1.8 2.2 
8 N116876 41.2 20 51.1 0.7   7729 140 2.5 3.1 
9 N088027 8.5 33.5 124.8 2.6 27.5 7015 90 18.7 20.3 
10 N104139                   
11 N128071 53.7 27 12.8 0.2 14.5 9158 61 2.9 1.9 
12 N114544                   
13 N105997                   
14 N114544                   
15 M711767                   
16 N136142 27.9 34.5 120.6 1.8 27 10045 101 5.6 11.8 
17 N140139                   
18 N113689                   
19 N140116                   
20 N049871                   
21 N167349                   
22 M791130                   
23 N176296                   
24 N106564                   
25 N182038                   
26 N143357                   
27 N032451                   
28 N143357 24.9 29 112.8 2.4 26 5947 138 2.4 10.9 
29 N168579 25.8 82.8 248.4 4.6 38.5 7244 165 16 26.4 
30 N168579 19.9 91 297 5.5 41.5 7314 91 1 12.1 
31 N184220                   
32 N214557                   
33 N173722                   
34 N211185                   
35 N214081 28.1 32 91.84 2 23.2 6903 157 2.5 0.3 
36 N172910                   
37 N218398                   
38 M001071                   
39 N083268                   
40 N211483                   
41 M955006                   
42 M837505 29.6 15.4 37.8 0.7 13.5 8804 145 4.5 9.1 
43 M924781                   
44 N246502                   
45 M237724                   
46 N248310                   
47 N239635 31.6 12.3 88.36 1.21 10.72 9308 183 5.4 1.6 
48 M727727                   
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APPENDIX IV 
Table 7 : COLLECTION EFFICIENCY 
No Patient’s ID 
Collection 
Efficiency Day 1 
Collection 
Efficiency Day 2 
Collection 
Efficiency Day 3 
1 N007209       
2 N063986       
3 N098229       
4 N102705       
5 N102713       
6 N098229       
7 N107407     30.35% 
8 N116876 50.0%     
9 N088027 70.8% 112.2% 58.33% 
10 N104139 59.1% 52.1%   
11 N128071 34.1% 10.5% 6.74% 
12 N114544 16.0% 23.1%   
13 N105997   79.2%   
14 N114544 67.8% 115.7%   
15 M711767 63.6% 85.3%   
16 N136142 21.9% 78.7% 39.04% 
17 N140139 33.7% 80.0%   
18 N113689 45.0%     
19 N140116       
20 N049871 71.9%     
21 N167349 29.3% 59.7%   
22 M791130 71.6%     
23 N176296 47.1%     
24 N106564 66.4%     
25 N182038 46.8%     
26 N143357 19.2% 25.7%   
27 N032451 58.1% 103.6%   
28 N143357 24.1% 130.4% 68.97% 
29 N168579 53.1% 64.2% 56.54% 
30 N168579 69.7% 119.8% 61.29% 
31 N184220 48.3% 63.3%   
32 N214557 66.8%     
33 N173722 70.1%     
34 N211185 58.8%     
35 N214081 92.7% 38.1% 48.20% 
36 N172910 57.8% 110.3%   
37 N218398 65.4%     
38 M001071 61.6% 65.4%   
39 N083268 75.3% 100.1%   
40 N211483 79.6%     
41 M955006 67.1% 119.5%   
42 M837505 63.6% 37.0% 29.71% 
43 M924781 5.5% 85.2%   
44 N246502 69.1% 52.9%   
45 M237724 77.6% 112.5%   
46 N248310 116.2% 87.0%   
47 N239635 92.5% 104.1% 82.48% 
48 M727727 63.7% 137.3%   
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APPENDIX V 
CORRELATION RESULT 
1) Pre-apheresis Peripheral Blood CD34
+
 Cells and Product Yield  
a) Overall pre-apheresis peripheral blood CD34
+
 cells and stem cell yield for 
day 1, 2 and 3 PBSC harvesting 
 
Table 8 (a): Correlation Result of Overall pre-apheresis peripheral blood CD34
+
 cells 
and stem cell yield for day 1, 2 and 3 PBSC harvesting 
  
  PRE_CD34_COUNT POST_CD34_YIELD 
PRE_CD34_COUNT Pearson Correlation 1 .963(**) 
  Sig. (2-tailed)   .000 
  N 94 94 
POST_CD34_YIELD Pearson Correlation .963(**) 1 
  Sig. (2-tailed) .000   
  N 94 94 
   
  **  Correlation is significant at the 0.01 level (2-tailed). 
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Figure 19(a): Correlation Analysis of Overall pre-apheresis peripheral blood CD34
+
 cells and 
                       stem cell yield for day 1, 2 and 3 PBSC harvesting 
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b) Pre-apheresis peripheral blood CD34+ cells and stem cell yield for day 1 
PBSC harvesting 
 
Table 8 (b): Correlation Result of Pre-apheresis peripheral blood CD34
+
 cells and stem 
cell yield for day 1 PBSC harvesting                                   
  
    PRECD34DAY1 POSTCD34YIELDDAY1 
PRECD34DAY1 Pearson Correlation 1 .967(**) 
  Sig. (2-tailed)   .000 
  N 48 48 
POSTCD34YIELDDAY1 Pearson Correlation .967(**) 1 
  Sig. (2-tailed) .000   
  N 48 48 
 
**  Correlation is significant at the 0.01 level (2-tailed). 
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Figure 19(b): Correlation Analysis of  Pre-apheresis peripheral blood CD34
+
 cells and stem 
   cell yield for day 1 PBSC harvesting 
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c) Pre-apheresis peripheral blood CD34
+
 cells and stem cell yield for day 2 
harvesting 
 
 
 Table 8 (c): Correlation Result Pre-apheresis peripheral blood CD34
+
 cells and stem 
                       cell yield for day 2 harvesting 
 
  
  PRECD34DAY2 POSTCD34YIELDDAY2 
PRECD34DAY2 Pearson Correlation 1 .913(**) 
  Sig. (2-tailed)   .000 
  N 35 35 
POSTCD34YIELDDAY2 Pearson Correlation .913(**) 1 
  Sig. (2-tailed) .000   
  N 35 35 
 
**  Correlation is significant at the 0.01 level (2-tailed). 
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Figure 19(c): Correlation Analysis of  Pre-apheresis peripheral blood CD34
+
 cells and stem     
                       cell yield for day 2 harvesting 
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d) Pre-apheresis peripheral blood CD34
+
 cells and stem cell yield for day 3 
harvesting 
 
 
 
Table 8 (d): Correlation Result of Pre-apheresis peripheral blood CD34
+
 cells and stem cell   
                     yield for day 3 harvesting 
 
    PRECD34DAY3 POSTCD34YIELDDAY3 
PRECD34DAY3 Pearson Correlation 1 .939(**) 
  Sig. (2-tailed)   .000 
  N 11 11 
POSTCD34YIELDDAY3 Pearson Correlation .939(**) 1 
  Sig. (2-tailed) .000   
  N 11 11 
 
**  Correlation is significant at the 0.01 level (2-tailed). 
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Figure 19(d): Correlation Analysis of Pre-apheresis peripheral blood CD34
+
 cells and stem   
                       cell yield for day 3 harvesting 
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 2) Post-apheresis Peripheral Blood CD34
+
 Cells  Day 1 and Day 2 Pre-  
            apheresis Peripheral Blood CD34
+
 Cells 
  
Table 9: Correlation Result of Post-apheresis Peripheral Blood CD34
+
 Cells  Day 1 and                
Day 2 Pre-apheresis Peripheral Blood CD34
+
 Cells 
 
   POST_PB_CD34COUNT PRE_CD34COUNT 
POST_PB_CD34COUNT Pearson Correlation 1 .895(**) 
  Sig. (2-tailed)   .000 
  N 28 28 
PRE_CD34COUNT Pearson Correlation .895(**) 1 
  Sig. (2-tailed) .000   
  N 28 28 
 
**  Correlation is significant at the 0.01 level (2-tailed). 
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Figure 20: Correlation Analysis of Post-apheresis Peripheral Blood CD34
+
 Cells  Day 1 and 
                 Day 2 Pre-apheresis Peripheral Blood CD34
+
 Cells 
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3) Post-apheresis Peripheral Blood CD34
+
 Cells  Day 1 and  Day 2 Stem Cell 
 Yield 
 
Table 10: Correlation Result Post-apheresis Peripheral Blood CD34
+
 Cells  Day 1 and  Day 2                 
Stem Cell Yield 
   POST_PBDAY1 SC_YIELD_DAY2 
POST_PBDAY1 Pearson Correlation 1 .811(**) 
  Sig. (2-tailed)   .000 
  N 28 28 
SC_YIELD_DAY2 Pearson Correlation .811(**) 1 
  Sig. (2-tailed) .000   
  N 28 28 
  
  **  Correlation is significant at the 0.01 level (2-tailed). 
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Figure 21: Correlation Result Post-apheresis Peripheral Blood CD34
+
 Cells  Day 1 and  Day   
                  2 Stem Cell Yield 
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APPENDIX VI 
RECEIVER OPERATING CHARACTERISTIC CURVE 
PREEDAY
0 20 40 60 80 100
0
20
40
60
80
100
100-Specificity
S
e
n
s
it
iv
it
y
 Sensitivity: 95.0
 Specificity: 82.4
 Criterion : >27
 
Figure 22(a): ROC Curve of Overall Pre-Apheresis Peripheral Blood CD34
+
  
              Cells and Stem Cell Yield for Day 1, 2 and 3 PBSC Harvesting 
 
 
 
 
Area under the ROC curve (AUC)  0.935 
Standard Error 
a
 0.0248 
95% Confidence Interval 
b
 0.864 to 0.975 
z statistic  17.501 
Significance level P (Area=0.5) <0.0001 
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Table 11(a): Criterion Values and Coordinates of the ROC Curve for Day 1, 2 and 3 PBSC                   
Harvesting 
         
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>=9.5 100 94.0 -
 100.0 
0 0.0 - 10.3 1   63.8   
>9.5 100 94.0 -
 100.0 
2.94 0.07 - 15.3 1.03 0 64.5 100 
>10.5 100 94.0 -
 100.0 
5.88 0.7 - 19.7 1.06 0 65.2 100 
>10.7 100 94.0 -
 100.0 
8.82 1.9 - 23.7 1.1 0 65.9 100 
>10.9 100 94.0 -
 100.0 
11.76 3.3 - 27.5 1.13 0 66.7 100 
>11.6 100 94.0 -
 100.0 
14.71 5.0 - 31.1 1.17 0 67.4 100 
>12 100 94.0 -
 100.0 
17.65 6.8 - 34.5 1.21 0 68.2 100 
>12.3 100 94.0 -
 100.0 
20.59 8.7 - 37.9 1.26 0 69 100 
>13 100 94.0 -
 100.0 
23.53 10.7 - 41.2 1.31 0 69.8 100 
>14 100 94.0 -
 100.0 
26.47 12.9 - 44.4 1.36 0 70.6 100 
>14.9 100 94.0 -
 100.0 
29.41 15.1 - 47.5 1.42 0 71.4 100 
>15.4 100 94.0 -
 100.0 
32.35 17.4 - 50.5 1.48 0 72.3 100 
>15.5 100 94.0 -
 100.0 
35.29 19.7 - 53.5 1.55 0 73.2 100 
>16 100 94.0 -
 100.0 
38.24 22.2 - 56.4 1.62 0 74.1 100 
>16.9 100 94.0 -
 100.0 
41.18 24.6 - 59.3 1.7 0 75 100 
>17 100 94.0 -
 100.0 
44.12 27.2 - 62.1 1.79 0 75.9 100 
>17.2 100 94.0 -
 100.0 
47.06 29.8 - 64.9 1.89 0 76.9 100 
>19 98.33 91.1 -
 100.0 
47.06 29.8 - 64.9 1.86 0.035 76.6 94.1 
>20 98.33 91.1 -
 100.0 
50 32.4 - 67.6 1.97 0.033 77.6 94.4 
>20.7 98.33 91.1 -
 100.0 
52.94 35.1 - 70.2 2.09 0.031 78.7 94.7 
>21.3 98.33 91.1 -
 100.0 
55.88 37.9 - 72.8 2.23 0.03 79.7 95 
>22 98.33 91.1 -
 100.0 
61.76 43.6 - 77.8 2.57 0.027 81.9 95.5 
>22.8 98.33 91.1 -
 100.0 
64.71 46.5 - 80.3 2.79 0.026 83.1 95.7 
>23 98.33 91.1 -
 100.0 
67.65 49.5 - 82.6 3.04 0.025 84.3 95.8 
>24 96.67 88.5 - 99.6 67.65 49.5 - 82.6 2.99 0.049 84.1 92 
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Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>24.5 96.67 88.5 - 99.6 70.59 52.5 - 84.9 3.29 0.047 85.3 92.3 
>25 95 86.1 - 99.0 70.59 52.5 - 84.9 3.23 0.071 85.1 88.9 
>25.5 95 86.1 - 99.0 73.53 55.6 - 87.1 3.59 0.068 86.4 89.3 
>26.5 95 86.1 - 99.0 76.47 58.8 - 89.3 4.04 0.065 87.7 89.7 
>27 * 95 86.1 - 99.0 82.35 65.5 - 93.2 5.38 0.061 90.5 90.3 
>28 91.67 81.6 - 97.2 82.35 65.5 - 93.2 5.19 0.1 90.2 84.8 
>28.5 90 79.5 - 96.2 82.35 65.5 - 93.2 5.1 0.12 90 82.4 
>29 86.67 75.4 - 94.1 82.35 65.5 - 93.2 4.91 0.16 89.7 77.8 
>29.3 85 73.4 - 92.9 82.35 65.5 - 93.2 4.82 0.18 89.5 75.7 
>29.5 85 73.4 - 92.9 85.29 68.9 - 95.0 5.78 0.18 91.1 76.3 
>29.8 83.33 71.5 - 91.7 85.29 68.9 - 95.0 5.67 0.2 90.9 74.4 
>30 80 67.7 - 89.2 85.29 68.9 - 95.0 5.44 0.23 90.6 70.7 
>32 75 62.1 - 85.3 85.29 68.9 - 95.0 5.1 0.29 90 65.9 
>32.7 73.33 60.3 - 83.9 85.29 68.9 - 95.0 4.99 0.31 89.8 64.4 
>32.8 73.33 60.3 - 83.9 88.24 72.5 - 96.7 6.23 0.3 91.7 65.2 
>33.5 71.67 58.6 - 82.5 88.24 72.5 - 96.7 6.09 0.32 91.5 63.8 
>33.7 70 56.8 - 81.2 88.24 72.5 - 96.7 5.95 0.34 91.3 62.5 
>34 68.33 55.0 - 79.7 88.24 72.5 - 96.7 5.81 0.36 91.1 61.2 
>34.5 68.33 55.0 - 79.7 91.18 76.3 - 98.1 7.74 0.35 93.2 62 
>37 66.67 53.3 - 78.3 91.18 76.3 - 98.1 7.56 0.37 93 60.8 
>40 65 51.6 - 76.9 94.12 80.3 - 99.3 11.0
5 
0.37 95.1 60.4 
>40.5 63.33 49.9 - 75.4 94.12 80.3 - 99.3 10.7
7 
0.39 95 59.3 
>41 61.67 48.2 - 73.9 94.12 80.3 - 99.3 10.4
8 
0.41 94.9 58.2 
>41.5 60 46.5 - 72.4 94.12 80.3 - 99.3 10.2 0.43 94.7 57.1 
>42.1 60 46.5 - 72.4 97.06 84.7 - 99.9 20.4 0.41 97.3 57.9 
>46 60 46.5 - 72.4 100 89.7 - 100.0   0.4 100 58.6 
>48 58.33 44.9 - 70.9 100 89.7 - 100.0   0.42 100 57.6 
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Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>49 56.67 43.2 - 69.4 100 89.7 - 100.0   0.43 100 56.7 
>51 55 41.6 - 67.9 100 89.7 - 100.0   0.45 100 55.7 
>51.2 53.33 40.0 - 66.3 100 89.7 - 100.0   0.47 100 54.8 
>51.5 51.67 38.4 - 64.8 100 89.7 - 100.0   0.48 100 54 
>54.1 50 36.8 - 63.2 100 89.7 - 100.0   0.5 100 53.1 
>55.5 48.33 35.2 - 61.6 100 89.7 - 100.0   0.52 100 52.3 
>58 46.67 33.7 - 60.0 100 89.7 - 100.0   0.53 100 51.5 
>58.5 45 32.1 - 58.4 100 89.7 - 100.0   0.55 100 50.7 
>59 43.33 30.6 - 56.8 100 89.7 - 100.0   0.57 100 50 
>64.5 40 27.6 - 53.5 100 89.7 - 100.0   0.6 100 48.6 
>65.5 38.33 26.1 - 51.8 100 89.7 - 100.0   0.62 100 47.9 
>65.9 36.67 24.6 - 50.1 100 89.7 - 100.0   0.63 100 47.2 
>73.4 35 23.1 - 48.4 100 89.7 - 100.0   0.65 100 46.6 
>74 33.33 21.7 - 46.7 100 89.7 - 100.0   0.67 100 45.9 
>75 31.67 20.3 - 45.0 100 89.7 - 100.0   0.68 100 45.3 
>76.5 30 18.8 - 43.2 100 89.7 - 100.0   0.7 100 44.7 
>81 28.33 17.5 - 41.4 100 89.7 - 100.0   0.72 100 44.2 
>82.8 26.67 16.1 - 39.7 100 89.7 - 100.0   0.73 100 43.6 
>89 25 14.7 - 37.9 100 89.7 - 100.0   0.75 100 43 
>91 23.33 13.4 - 36.0 100 89.7 - 100.0   0.77 100 42.5 
>94 21.67 12.1 - 34.2 100 89.7 - 100.0   0.78 100 42 
>95.8 20 10.8 - 32.3 100 89.7 - 100.0   0.8 100 41.5 
>100 18.33 9.5 - 30.4 100 89.7 - 100.0   0.82 100 41 
>114 16.67 8.3 - 28.5 100 89.7 - 100.0   0.83 100 40.5 
>116.4 15 7.1 - 26.6 100 89.7 - 100.0   0.85 100 40 
>123.5 13.33 5.9 - 24.6 100 89.7 - 100.0   0.87 100 39.5 
>132 11.67 4.8 - 22.6 100 89.7 - 100.0   0.88 100 39.1 
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Figure 22(b): ROC Curve of Pre-apheresis Peripheral Blood CD34
+
 Cells and 
               Stem Cell Yield for Day 1 Harvesting 
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>156.9 10 3.8 - 20.5 100 89.7 - 100.0   0.9 100 38.6 
>159 8.33 2.8 - 18.4 100 89.7 - 100.0   0.92 100 38.2 
>194 6.67 1.8 - 16.2 100 89.7 - 100.0   0.93 100 37.8 
>256.5 5 1.0 - 13.9 100 89.7 - 100.0   0.95 100 37.4 
>330 3.33 0.4 - 11.5 100 89.7 - 100.0   0.97 100 37 
>371 1.67 0.04 - 8.9 100 89.7 - 100.0   0.98 100 36.6 
>456.5 0 0.0 - 6.0 100 89.7 - 100.0 
 
  1   36.2 
 
Area under the ROC curve (AUC)  0.895 
Standard Error 
a
 0.0451 
95% Confidence Interval 
b
 0.772 to 0.965 
z statistic  8.767 
Significance level P (Area=0.5) <0.0001 
 
a
 Hanley & McNeil, 1982  
 
b
 Binomial exact 
  
 
Sensitivity: 94.1 
Specificity: 71.4 
Criterion:  >27 
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Table 11(b): Criterion Values and Coordinates of the ROC Curve for Day 1                     
PBSC Harvesting 
 
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>=9.5 100 89.7 -
 100.0 
0 0.0 - 23.2 1   70.8   
>9.5 100 89.7 -
 100.0 
7.14 0.2 - 33.9 1.08 0 72.3 100 
>13 100 89.7 -
 100.0 
14.29 1.8 - 42.8 1.17 0 73.9 100 
>14.9 100 89.7 -
 100.0 
21.43 4.7 - 50.8 1.27 0 75.6 100 
>16.9 100 89.7 -
 100.0 
28.57 8.4 - 58.1 1.4 0 77.3 100 
>17.2 100 89.7 -
 100.0 
35.71 12.8 - 64.9 1.56 0 79.1 100 
>19 97.06 84.7 -
 99.9 
35.71 12.8 - 64.9 1.51 0.082 78.6 83.3 
>20.7 97.06 84.7 -
 99.9 
42.86 17.7 - 71.1 1.7 0.069 80.5 85.7 
>22 97.06 84.7 -
 99.9 
50 23.0 - 77.0 1.94 0.059 82.5 87.5 
>23 97.06 84.7 -
 99.9 
57.14 28.9 - 82.3 2.26 0.051 84.6 88.9 
>24 94.12 80.3 -
 99.3 
57.14 28.9 - 82.3 2.2 0.1 84.2 80 
>24.5 94.12 80.3 -
 99.3 
64.29 35.1 - 87.2 2.64 0.092 86.5 81.8 
>27 * 94.12 80.3 -
 99.3 
71.43 41.9 - 91.6 3.29 0.082 88.9 83.3 
>28 88.24 72.5 -
 96.7 
71.43 41.9 - 91.6 3.09 0.16 88.2 71.4 
>29.3 85.29 68.9 -
 95.0 
71.43 41.9 - 91.6 2.99 0.21 87.9 66.7 
>29.5 85.29 68.9 -
 95.0 
78.57 49.2 - 95.3 3.98 0.19 90.6 68.7 
>29.8 82.35 65.5 -
 93.2 
78.57 49.2 - 95.3 3.84 0.22 90.3 64.7 
>30 76.47 58.8 -
 89.3 
78.57 49.2 - 95.3 3.57 0.3 89.7 57.9 
>32 70.59 52.5 -
 84.9 
78.57 49.2 - 95.3 3.29 0.37 88.9 52.4 
>32.7 67.65 49.5 -
 82.6 
78.57 49.2 - 95.3 3.16 0.41 88.5 50 
>32.8 67.65 49.5 -
 82.6 
85.71 57.2 - 98.2 4.74 0.38 92 52.2 
>33.7 64.71 46.5 -
 80.3 
85.71 57.2 - 98.2 4.53 0.41 91.7 50 
>37 61.76 43.6 -
 77.8 
85.71 57.2 - 98.2 4.32 0.45 91.3 48 
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Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>40 61.76 43.6 -
 77.8 
92.86 66.1 - 99.8 8.65 0.41 95.5 50 
>40.5 58.82 40.7 -
 75.4 
92.86 66.1 - 99.8 8.24 0.44 95.2 48.1 
>42.1 58.82 40.7 -
 75.4 
100 76.8 -
 100.0 
  0.41 100 50 
>49 55.88 37.9 -
 72.8 
100 76.8 -
 100.0 
  0.44 100 48.3 
>51.5 52.94 35.1 -
 70.2 
100 76.8 -
 100.0 
  0.47 100 46.7 
>58 50 32.4 -
 67.6 
100 76.8 -
 100.0 
  0.5 100 45.2 
>58.5 47.06 29.8 -
 64.9 
100 76.8 -
 100.0 
  0.53 100 43.7 
>59 44.12 27.2 -
 62.1 
100 76.8 -
 100.0 
  0.56 100 42.4 
>65.5 41.18 24.6 -
 59.3 
100 76.8 -
 100.0 
  0.59 100 41.2 
>65.9 38.24 22.2 -
 56.4 
100 76.8 -
 100.0 
  0.62 100 40 
>73.4 35.29 19.7 -
 53.5 
100 76.8 -
 100.0 
  0.65 100 38.9 
>75 32.35 17.4 -
 50.5 
100 76.8 -
 100.0 
  0.68 100 37.8 
>94 29.41 15.1 -
 47.5 
100 76.8 -
 100.0 
  0.71 100 36.8 
>114 26.47 12.9 -
 44.4 
100 76.8 -
 100.0 
  0.74 100 35.9 
>116.4 23.53 10.7 -
 41.2 
100 76.8 -
 100.0 
  0.76 100 35 
>123.5 20.59 8.7 - 37.9 100 76.8 -
 100.0 
  0.79 100 34.1 
>132 17.65 6.8 - 34.5 100 76.8 -
 100.0 
  0.82 100 33.3 
>159 14.71 5.0 - 31.1 100 76.8 -
 100.0 
  0.85 100 32.6 
>194 11.76 3.3 - 27.5 100 76.8 -
 100.0 
  0.88 100 31.8 
>256.5 8.82 1.9 - 23.7 100 76.8 -
 100.0 
  0.91 100 31.1 
>330 5.88 0.7 - 19.7 100 76.8 -
 100.0 
  0.94 100 30.4 
>371 2.94 0.07 -
 15.3 
100 76.8 -
 100.0 
  0.97 100 29.8 
>456.5 0 0.0 - 10.3 100 76.8 -
 100.0 
  1   29.2 
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Figure 22(c): ROC Curve of Pre-apheresis Peripheral Blood CD34
+
 Cells and 
               Stem Cell Yield for Day 2 Harvesting 
 
 
 
 
 
 
 
 
 
 
 
 
 
Area under the ROC curve (AUC)  0.969 
Standard Error 
a
 0.0284 
95% Confidence Interval 
b
 0.848 to 0.999 
z statistic  16.525 
Significance level P (Area=0.5) <0.0001 
 
a
 Hanley & McNeil, 1982  
 
b
 Binomial exact  
 
 
Sensitivity: 95.3 
Specificity: 92.9 
Criterion:  >26.5 
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Table 11(c): Criterion Values and Coordinates of the ROC Curve for Day 2  PBSC 
Harvesting 
 
 
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>=10.5 100 83.9 -
 100.0 
0 0.0 - 23.2 1   60   
>10.5 100 83.9 -
 100.0 
7.14 0.2 - 33.9 1.08 0 61.8 100 
>10.9 100 83.9 -
 100.0 
14.29 1.8 - 42.8 1.17 0 63.6 100 
>11.6 100 83.9 -
 100.0 
21.43 4.7 - 50.8 1.27 0 65.6 100 
>12 100 83.9 -
 100.0 
28.57 8.4 - 58.1 1.4 0 67.7 100 
>14 100 83.9 -
 100.0 
35.71 12.8 -
 64.9 
1.56 0 70 100 
>15.5 100 83.9 -
 100.0 
42.86 17.7 -
 71.1 
1.75 0 72.4 100 
>16 100 83.9 -
 100.0 
50 23.0 -
 77.0 
2 0 75 100 
>17 100 83.9 -
 100.0 
57.14 28.9 -
 82.3 
2.33 0 77.8 100 
>21.3 100 83.9 -
 100.0 
64.29 35.1 -
 87.2 
2.8 0 80.8 100 
>22 100 83.9 -
 100.0 
71.43 41.9 -
 91.6 
3.5 0 84 100 
>22.8 100 83.9 -
 100.0 
78.57 49.2 -
 95.3 
4.67 0 87.5 100 
>25 95.24 76.2 -
 99.9 
78.57 49.2 -
 95.3 
4.44 0.061 87 91.7 
>25.5 95.24 76.2 -
 99.9 
85.71 57.2 -
 98.2 
6.67 0.056 90.9 92.3 
>26.5 * 95.24 76.2 -
 99.9 
92.86 66.1 -
 99.8 
13.33 0.051 95.2 92.9 
>28.5 90.48 69.6 -
 98.8 
92.86 66.1 -
 99.8 
12.67 0.1 95 86.7 
>29 85.71 63.7 -
 97.0 
92.86 66.1 -
 99.8 
12 0.15 94.7 81.2 
>34 80.95 58.1 -
 94.6 
92.86 66.1 -
 99.8 
11.33 0.21 94.4 76.5 
>40 76.19 52.8 -
 91.8 
92.86 66.1 -
 99.8 
10.67 0.26 94.1 72.2 
>41 71.43 47.8 -
 88.7 
92.86 66.1 -
 99.8 
10 0.31 93.7 68.4 
>41.5 66.67 43.0 -
 85.4 
92.86 66.1 -
 99.8 
9.33 0.36 93.3 65 
>46 66.67 43.0 -
 85.4 
100 76.8 -
 100.0 
  0.33 100 66.7 
>48 61.9 38.4 -
 81.9 
100 76.8 -
 100.0 
  0.38 100 63.6 
>51 57.14 34.0 -
 78.2 
100 76.8 -
 100.0 
  0.43 100 60.9 
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Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>51.2 52.38 29.8 -
 74.3 
100 76.8 -
 100.0 
  0.48 100 58.3 
>54.1 47.62 25.7 -
 70.2 
100 76.8 -
 100.0 
 
  0.52 100 56 
>55.5 42.86 21.8 -
 66.0 
100 76.8 -
 100.0 
  0.57 100 53.8 
>64.5 33.33 14.6 -
 57.0 
100 76.8 -
 100.0 
  0.67 100 50 
>74 28.57 11.3 -
 52.2 
100 76.8 -
 100.0 
  0.71 100 48.3 
>76.5 23.81 8.2 - 47.2 100 76.8 -
 100.0 
  0.76 100 46.7 
>81 19.05 5.4 - 41.9 100 76.8 -
 100.0 
  0.81 100 45.2 
>89 14.29 3.0 - 36.3 100 76.8 -
 100.0 
  0.86 100 43.7 
>95.8 9.52 1.2 - 30.4 100 76.8 -
 100.0 
  0.9 100 42.4 
>100 4.76 0.1 - 23.8 100 76.8 -
 100.0 
  0.95 100 41.2 
>156.9 0 0.0 - 16.1 100 76.8 -
 100.0 
  1   40 
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Figure 22(d): ROC Curve of Pre-apheresis Peripheral Blood CD34
+
 Cells and 
   Stem Cell Yield for Day 3 Harvesting 
 
 
Sensitivity: 100 
Specificity: 83.4 
Criterion:  >27 
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Area under the ROC curve (AUC)  0.9 
Standard Error 
a
 0.106 
95% Confidence Interval 
b
 0.576 to 0.997 
z statistic  3.78 
Significance level P (Area=0.5) 0.0002 
 
a
 Hanley & McNeil, 1982  
 
b
 Binomial exact  
 
 
Table 11(d): Criterion Values and Coordinates of the ROC Curve for Day 3           
PBSC Harvesting 
 
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR +PV -PV 
>=10.7 100 47.8 -
 100.0 
0 0.0 - 45.9 1   45.5   
>10.7 100 47.8 -
 100.0 
16.67 0.4 - 64.1 1.2 0 50 100 
>12.3 100 47.8 -
 100.0 
33.33 4.3 - 77.7 1.5 0 55.6 100 
>15.4 100 47.8 -
 100.0 
50 11.8 -
 88.2 
2 0 62.5 100 
>20 100 47.8 -
 100.0 
66.67 22.3 -
 95.7 
3 0 71.4 100 
>27 * 100 47.8 -
 100.0 
83.33 35.9 -
 99.6 
6 0 83.3 100 
>29 80 28.4 -
 99.5 
83.33 35.9 -
 99.6 
4.8 0.24 80 83.3 
>32 60 14.7 -
 94.7 
83.33 35.9 -
 99.6 
3.6 0.48 75 71.4 
>33.5 40 5.3 - 85.3 83.33 35.9 -
 99.6 
2.4 0.72 66.7 62.5 
>34.5 40 5.3 - 85.3 100 54.1 -
 100.0 
  0.6 100 66.7 
>82.8 20 0.5 - 71.6 100 54.1 -
 100.0 
  0.8 100 60 
>91 0 0.0 - 52.2 100 54.1 -
 100.0 
  1   54.5 
 
 
 
